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Prostate cancer is the second leading cause of cancer-related 
death and the most common non-skin cancer in men in the USA. 
Considerable advancements in the practice of medicine have allowed a 
significant improvement in the diagnosis and treatment of this disease 
and, in recent years, both incidence and mortality rates have been slightly 
declining. However, it is still estimated that 1 man in 6 will be diagnosed 
with prostate cancer during his lifetime, and 1 man in 35 will die of the 
disease.  
In order to identify novel strategies and effective therapeutic 
approaches in the fight against prostate cancer, it is imperative to improve 
our understanding of its complex biology since many aspects of prostate 
 vi 
cancer initiation and progression still remain elusive. The study of tumor 
biomarkers, due to their specific altered expression in tumor versus 
normal tissue, is a valid tool for elucidating key aspects of cancer biology, 
and may provide important insights into the molecular mechanisms 
underlining the tumorigenesis process of prostate cancer.  
PCA3, is considered the most specific prostate cancer biomarker, 
however its biological role, until now, remained unknown. PCA3 is a long 
non-coding RNA (ncRNA) expressed from chromosome 9q21 and its 
study led us to the discovery of a novel human gene, PC-TSGC, 
transcribed from the opposite strand and in an antisense orientation to 
PCA3. 
With the work presented in this thesis, we demonstrate that PCA3 
exerts a negative regulatory role over PC-TSGC, and we propose PC-
TSGC to be a new tumor suppressor gene that contrasts the 
transformation of prostate cells by inhibiting Rho-GTPases signaling 
pathways. Our findings provide a biological role for PCA3 in prostate 
cancer and suggest a new mechanism of tumor suppressor gene 
inactivation mediated by non-coding RNA. Also, the characterization of 
PCA3 and PC-TSGC led us to propose a new molecular pathway 
involving both genes in the transformation process of the prostate, thus 
providing a new piece of the jigsaw puzzle representing the complex 
biology of prostate cancer.  
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CHAPTER 1:  
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 Functions and biological significance of non-coding 
RNAs in eukaryotes: an overview  
 
In the past twenty years, a significant number of discoveries in the 
RNA molecular biology field led the scientific community to the revision of 
the central dogma of biology: “DNA makes RNA makes protein”. This 
classical view is no longer entirely true as it is now clear that RNA is not 
“just” a molecule that translates the genetic information into proteins 
(Carnici et al., 2008). Up to recent years, apart from mRNAs the only other 
RNA classes that were recognized to have a biological function were 
rRNA, tRNA and the RNA components of the spliceosome (snRNA), 
however the scientific community was still unaware of the enormous role 
of RNA in several other aspects of cellular life.  
After the sequencing of the human genome, scientists realized that 
only a small percentage of the whole genome is actually transcribed into 
coding sequences that eventually are translated into proteins, and the rest 
of the DNA that does not contain coding regions was merely referred to as 
“junk DNA”. Also, transcription of non-coding regions was considered 
“transcriptional noise” (Louro et al., 2009). No other definition could have 
been less accurate than these two.   
After the discovery of the first miRNA, lin-4 (Lee et al., 1993), 
scientists realized that RNA could have important regulatory functions also 
in eukaryotes, considering that antisense RNA was already known to 
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regulate gene expression in bacteria (Brantl, 2007). However, only in the 
last 10 years, after the discovery of RNA interference, biologists really 
learned that the majority of the genome is actually functionally transcribed, 
and that non-coding RNAs are important in many aspects of cellular life, 
with particular attention to gene expression regulation (Amaral et al., 
2008).  
Ever since, many different classes of regulatory RNA have been 
discovered and most likely many more are still unknown (Storz et al., 
2005). A precise classification of all the RNA classes is not yet available. 
Thus scientists generally classify them according to their size, biogenesis, 
interacting partner proteins and function (Amaral et al., 2008). However 
the boundaries for each class is not always well defined and RNA 
nomenclature is not always accurate in relation to all the several classes 
that have been discovered so far. 
 
In general, RNA classes involved in the regulation of gene 
expression can be divided into two main groups: 
• Small non coding RNAs  
• Long non coding RNAs  
 
The distinction between small and long ncRNAs is just based on 
the fact that lncRNAs are arbitrarily considered to be longer than 200 nt, 
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on the basis of a practical cut-off in RNA purification protocols that 
excludes small RNAs (Storz et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
1.2 Small non-coding RNAs 
 
 Small ncRNAs are the most studied and well-characterized classes 
of regulatory RNAs. Among them the most important are: 
 
Micro RNAs (miRNA):  miRNAs are short RNAs approximately 22 
nt long that usually act as regulators of translation but can also be 
involved in RNA degradation. miRNA may be expressed at high levels, up 
to tens of thousands of copies per cell, and play important regulatory roles 
by controlling hundreds of mRNA targets. They are transcribed by RNA 
polymerase II and transcripts are capped and polyadenylated. Half of all 
miRNAs are identified in clusters that are transcribed as polycistronic 
primary transcripts. Processing of the primary transcripts depends on the 
miRNA sequence folding into a stem-loop structure. A typical primary 
miRNA is cleaved by the complex Drosha-DGCR8, which is a RNase III 
family endonuclease, containing two RNase III domains and a dsRNA 
binding domain. The cleavage occurs 11nt from the base of the stem 
structure and the resulting pre-miRNA has a 5’-phosphate and a 3’ 2nt 
overhang. An alternative pathway uses splicing of pri-miRNA transcripts, 
in this case also called mirtrons, to liberate introns that precisely mimic the 
structural features of pre-miRNA. After this first processing step, pre-
miRNA are exported from the nucleus with a GTP-dependent transport 
mechanism to the cytoplasm, where they undergo a second processing 
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step operated by Dicer, which is another RNase III enzyme that excises 
the terminal loop from the pre-miRNA to create a mature miRNA of 
approximately 22nt. The miRNA processing machinery produces final 
miRNA duplexes molecules with very exact ends, and both Drosha and 
Dicer exploit RNA binding domains or accessory protein (DGR8) that allow 
the two enzymes to determine the cleavage sites in a ruler-like fashion. 
Next, the miRNA RISC (RNA Induced Silencing Complex) is formed by 
loading of one strand of the miRNA duplex onto a protein of the Argonaute 
family (Ago). Ago proteins are crucial effectors for the final silencing 
function of a miRNA and they can discriminate the miRNA strand to be 
loaded based on the relative thermodynamic stability of the miRNA ends: 
the strand with the lowest stability at the 5’ end will be loaded into the 
RISC, while the other strand (passenger strand) is discarded, however this 
rule is not absolute and many aspects of miRNA unwinding and loading 
into RISC are unclear. 
Once assembled, the miRNA acts as an adaptor for the RISC to 
specifically recognize and regulate target mRNAs. Generally, miRNA 
binding sites in animal mRNAs lie in the 3’UTR and usually are present in 
multiple copies. The recognition of the binding sites involves the 
nucleotides 2-8 of the miRNA, which represent the “seed” region. The 
degree of miRNA-mRNA complementarity determines the kind of 
regulatory mechanism adopted by the RISC: Perfect complementarity 
allows the cleavage of the mRNA strand by Ago. This cleavage is 
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operated by a domain of the Ago protein known as PIWI domain that acts 
as an RNase H endonuclease. Once the mRNA is cleaved, the exposed, 
unprotected ends are then susceptible to the attack of exonucleases. On 
the other hand, central mismatches of the miRNA-mRNA pair exclude 
cleavage, instead they promote repression of mRNA translation or 
removal of poly-A tails. In these cases, different mechanisms have been 
proposed: 
• The RISC may promote the premature ribosome 
dissociation from mRNA. 
• The RISC may compete with the elongation factor 
elF4E for binding to the mRNA capping structure, therefore 
inhibiting translation initiation. 
• The RISC may block association of the ribosomal 60S 
subunit with the 40S preinitiation complex. 
• The RISC may stimulate the de-adenylation of the 
mRNA tail, leading to mRNA degradation. 
 
It is possible that all these mechanisms may co-exist and even be 
synergistic. It is also very important to note that miRNA are able to 
stimulate protein translation under certain conditions. It seems that some 
miRNA inhibit translation in proliferating cells while they can stimulate 
translation during cell starvation. In another case, the binding of the 
miRNA at the 5’ or 3’UTR regions determines the stimulation or repression 
 8 
of translation, respectively. However, these do not represent general rules 
and also the mechanisms for stimulation of translation by miRNAs are not 
yet understood (Carthew et al., 2009; Wu et al., 2008).  
 
Small interfering RNAs (siRNA): siRNA processing and silencing 
mechanisms resemble those of miRNA in many steps of the RNA 
interference process. The main differences between siRNA and miRNA lie 
in the biogenesis and in the target mRNAs of these two molecules.  
In general, the term “siRNA” should include several sub-classes of 
small interfering RNAs, however “siRNA” is usually associated with a 
process that involves the cleavage of target mRNA molecules by a RISC 
complex loaded with a perfectly matching siRNA guide strand. The typical 
siRNA pathway is initiated in the cytoplasm when exogenous dsRNA 
enters the cell. Similarly to miRNAs, long dsRNA are processed by Dicer, 
which creates small dsRNAs with a 5’-phosphate 2nt overhang at the 3’ 
ends, then the 21-23nt  strand with lower relative thermodynamic stability 
at the 5’ end will be loaded onto an Ago protein as the siRNA guide 
strand. At this point the RISC effector complex will be formed. With perfect 
base pairing and formation of an A-form helix structure between the siRNA 
guide strand and its target mRNA, the RISC cleaves (with the PIWI 
domain of Ago) its target 10-11 nt from the 5’ end of the guide siRNA 
strand, and the complex is then recycled for the next round of target 
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mRNA cleavage. mRNAs cleaved by the RISC subsequently are 
degraded by cellular exonucleases. 
In some organisms, a siRNA amplification pathway was detected: a 
RNA-dependent RNA polymerase (RdRP) synthesized dsRNA from RNA 
cleaved by the RISC, and the synthesized dsRNA are used as siRNA 
precursors (Carthew et al., 2009; Wu et al., 2008). 
  
Since endogenous siRNA pathways initially were not detected, 
originally this mechanism was thought to represent a mean of defense 
against exongenous dsRNA introduced into a cell, such as a virus. 
However, more recently siRNA regulatory mechanisms have been 
identified also for endogenous sequences in different organisms, leading 
to the discovery of new sub-classification and new mechanisms of action 
of siRNAs (Farazi et al., 2008): 
 
Piwi-interacting RNAs (piRNA): piRNAs are a class of small RNA 
(25-29nt) involved in RNA silencing or transposable elements in the 
germline. piRNA biogenesis is Dicer-independent and they are generally 
processed from single-stranded primary transcripts that are clustered into 
a limited number of genomic loci, where only one strand encodes piRNAs 
mainly. 
Piwi-related proteins compose a sub-family belonging to the Ago 
family of effector proteins and they are specifically expressed in the 
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germline. Piwi proteins associate with piRNAs that act as guides in 
silencing target RNA. It is hypothesized that piRNAs are involved in the 
silencing of transposable elements during spermatogenesis (Kawaji et al., 
2008; Chu et al., 2007). 
 
Repeat-associated RNAs (rasiRNA): rasiRNAs originate from 
repetitive sequences such as transposons and are found in both the sense 
and antisense strands of transposable elements. rasiRNAs are suggested 
to repress the transposable elements themselves or mRNAs bearing 
sequences complementary to them. Also, rasiRNAs are involved in 
transcriptional silencing through chromatin modifications. Repetitive 
sequences frequently are found in chromatin domains, and it is suggested 
that rasiRNAs contribute to the regulation of chromatin status (Kawaji et 
al., 2008; Chu et al., 2007).  
 
Heterochromatic siRNAs (hcRNAs): hcRNAs are a particular class 
of siRNAs that derive from long dsRNA precursors that are transcribed 
from genomic repeat regions such as centromeric repeats. They are 
involved in the regulation of heterochromatin structures and mediate 
transcriptional gene regulation. They are loaded onto a particular Ago-
containing effector complex known as RITS (RNA Induced Transcriptional 
Silencing) and they guide the RITS to centromeric repeats by hcRNA 
recognition of nascent transcripts. The RITS is then involved in the 
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nucleation and maintenance of heterochromatin by recruiting histone 
methyltransferases. Engagement of nascent transcripts by the RITS also 
activates the RNA dependent RNA polymerase complex (RDRC) that 
uses its RdRP subunit to generate secondary hcRNAs. Also, in plants in 
addition of histone methylations, the RITS complex directly recruits DNA 
methyltransferases that contribute to the heterochromatin state (Kawaji et 
al., 2008; Chu et al., 2007). 
 
Trans-acting siRNAs (tasiRNA): tasiRNA is a class of siRNA that 
targets other genes rather than the gene producing the siRNA itself. It is 
found only in plants and it is derived from an mRNA cleaved by a miRNA. 
A cleaved product of the mRNA is then used as a template to synthesize 
dsRNA by a RdRP, and the resulting product then triggers RNA silencing 
to repress other genes (Kawaji et al., 2008; Chu et al., 2007).  
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1.3 Long non-coding RNAs 
 
Long non coding RNAs, the second main group of gene expression 
regulatory RNAs, were first described during large-scale sequencing of 
full-length mouse cDNA libraries (Ponting et al., 2009). Ever since, it has 
become apparent that a significant portion of the transcriptome has little or 
no protein-coding capacity and it is now known that the extent of non-
coding sequence transcription is at least four times greater than coding 
sequence (Louro et al., 2009; Mendes Soares et al., 2006; Amaral et al., 
2005). Long ncRNA often overlaps with, or intersperses between, multiple 
coding and non-coding transcripts and they are observed in a wide range 
of different tissues. These observations raise the possibility that genomic 
sequences can be transcribed into a range of sense and antisense, coding 
and non-coding transcripts. Most long ncRNAs tend to be transcribed 
away from the 5’ or 3’ ends of genes. Nevertheless, transcription of long 
ncRNAs has been found to be more concentrated near the promoters and 
initial exons and introns of genes (Mercer et al., 2009). So far, a 
classification of long ncRNA is only based on their genomic proximity to 
protein coding genes, including overlapping, antisense, bidirectional or 
intronic long ncRNAs, even though many transcripts resist classification 
into any particular category, and instead exhibit a combination of these 
qualities. 
 13 
Alongside tissue specificity, long ncRNAs transcription seems to be 
spatially restricted by subcellular expression preferences. For example, 
intronic long ncRNA expression appears predominantly nuclear, even 
though exceptions exist. Also, some long ncRNAs show unusual or unique 
localization patterns, thereby classifying entirely new subcellular 
compartments (Ponting et al., 2009; Mercer et al., 2009).  
Long ncRNAs genereally show low sequence conservation, 
however they have conserved secondary structures and splicing patterns 
suggesting different roles of long ncRNA in gene expression regulation. 
Transcription of long ncRNAs may regulate the expression of genes in 
close genomic proximity (cis-acting regulation) and to target distant 
transcriptional activators or repressors by a variety of mechanisms 
involving chromatin remodeling, transcriptional and post-transcriptional 
regulation (Mercer et al., 2009; Yazgan et al., 2007).  
Long ncRNAs may mediate epigenetic changes by recruiting 
chromatin remodeling complexes to specific genomic loci, where they 
define chromatin domains of differential histone methylation and RNA 
polymerase accessibility. These activities may be very important during 
development and for epigenetic phenomena such as imprinting and X 
chromosome inactivation. Another mechanism of chromatin remodeling 
involves the inhibition of the histone acetyltransferase activities of CREB 
binding proteins and p300 in order to silence target genes expression.  
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Apart from determining DNA accessibility by recruiting of chromatin 
remodeling complexes, it is suggested that the process of transcription of 
a long ncRNA per se, rather than the product of transcription, actually 
regulates transcription of target genes. These regulations are either 
positive or negative. For example, the active transcription of a long ncRNA 
may disrupt chromatin structure causing progressive opening of chromatin 
and promote the accessibility of protein-coding genes to RNA polymerase. 
Conversely, a negative regulation may result from collisions between 
transcriptional machineries that are processing along adjacent sequences. 
When elongation of one transcriptional event proceeds through a promoter 
sequence it suppresses this sequence’s ability to initiate a second 
transcriptional event (Ponting et al., 2009; Munroe et al., 2006).     
 
Long ncRNAs also act as co-factors to modulate transcription factor 
activity. For example, they recruit the binding and action of transcription 
factors to enhancers and then induce expression of adjacent protein-
coding genes. Also, long ncRNAs may regulate RNA polymerase II activity 
through direct binding to DNA sequences. For example, transcribed long 
ncRNA forms a triplex with adjacent promoter regions and therefore 
inhibits binding of transcription factors and the formation of the pre-
initiation complex required for gene transcription (Yazgan et al., 2007).. 
Long ncRNA also effects global changes by interacting with basal 
components of the RNA polymerase II transcription machinery. Such long 
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ncRNAs are typically transcribed by RNA polymerase III, thereby 
decoupling their expression from the RNA polymerase II–dependent 
transcription reaction they regulate. Other long ncRNAs regulate 
transcription indirectly by controlling the subcellular localization of 
transcription factors to the cytoplasm and preventing them to access the 
nucleus, maybe by interactions with nuclear transport factors (Yazgan et 
al., 2007). 
 
Many long ncRNA are transcribed antisense to corresponding 
genes and the ability of long ncRNA to recognize complementary 
sequences also allows highly specific interactions that regulate different 
steps in the post-transcriptional processing of mRNAs, including their 
splicing, editing, transport, translation and degradation. Antisense long 
ncRNAs can mask key cis elements in mRNA by the formation of RNA 
duplexes. This leads to alternative splicing event of the target mRNA by 
masking or exposing differential splice sites, or to the RNA editing of the 
annealed RNA sequences by specific double-strand RNA binding proteins 
such as ADAR1 and ADAR2. Another possibility of control by long ncRNA 
is that antisense long ncRNA stabilizes protein-coding RNA transcribed 
from the same genomic loci, which otherwise would undergo degradation 
(Munroe et al., 2006; Katayama et al., 2005).  
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Finally, the annealing of ncRNA may possibly target protein effector 
complexes to the sense mRNA transcript in a manner analogous to the 
targeting of the RISC to mRNA by miRNAs and siRNAs. RNA duplexes 
resulting from the annealing of complementary transcripts or even of long 
ncRNAs with extended internal hairpins may be processed into 
endogenous siRNA to silence gene expression, raising the possibility that 
long ncRNA feed into RNA interference silencing pathways.  Some long 
ncRNAs transcripts are also spliced, polyadenylated and exported into the 
cytoplasm; their functions is not fully understood but it is also interesting to 
ask how an RNA that is spliced and exported from the nucleus evades 
destruction by the nonsense mediated decay pathway (Ponting et al., 
2009; Mercer et al., 2009).  
There are probably many other functions of long ncRNAs that have 
not been proposed yet and this particular field of research is now in rapid 
expansion. 
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1.4 Long ncRNAs in prostate cancer 
 
A class of long ncRNAs that maps to genomic regions 
corresponding to intronic sequences located on their opposite DNA strand 
(intronic-antisense ncRNAs), correlates with a number of events, including 
tumor grade in prostate cancer (Louro et al., 2007; Nakaya et al., 2007; 
Reis et al., 2004). Several lines of evidence indicate that intronic-
antisense ncRNA are also involved in the regulation of expression of the 
corresponding sense gene (Faghihi et al., 2008; Scheele et al., 2007; 
Louro et al., 2007; Katayama et al., 2005; Munroe et al., 2006; Tasheva et 
al., 1995). Also intronic-antisense ncRNA respond to androgen stimulation 
(Louro et al., 2007). Androgens are implicated in the regulation of several 
physiological and pathological processes in both normal and neoplastic 
prostate cells. 
These evidence suggests that intronic-antisense ncRNA may play a 
key role in the tumorigenesis process of PCa, possibly by regulating the 
gene expression levels as well as splicing variants of their corresponding 
sense gene.  
In particular, PCA3 is a ncRNA that is specifically enhanced in 
human prostate cancer and appears to be a promising biomarker in this 
tumor. The expression of PCA3 correlates with a cancerous state of the 
prostate and is prostate tissue-specific. Furthermore, PCA3 is responsive 
to androgen stimulation and its cellular location is mainly confined to the 
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nucleus (Schalken et al., 2003; de Kok et al., 2002).  However, though 
PCA3 can be easily considered as the most important ncRNA ever 
identified in PCa, and its significance as a new PCa biomarker bears 
enormous potential for the improvement of current methodologies in PCa 
diagnosis, functional characterization of PCA3 and potential biological 
roles still remain largely undetermined.  
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1.5 Pitfalls in PCa diagnosis: current challenges and new 
approaches 
 
One of the most important challenges in the management and 
treatment of prostate cancer is efficient prediction of disease outcome. 
Current diagnostic methodologies do not allow a precise risk assessment 
for the development and recurrence of aggressive prostate cancer (Troyer 
et al., 2004; Reynolds et al., 2007). Digital Rectal Examination (DRE) and 
monitoring of Prostate Specific Antigen (PSA) serum levels are the current 
standard assays that are employed for an initial assessment of prostate 
conditions, while a definitive diagnosis of prostate cancer is only 
determined upon the evaluation of prostate biopsies. Specifically, the 
severity of the disease is determined upon histological analysis with the 
assignment of a combined score according to the Gleason grading system 
(Gleason et al., 1974). The Gleason score is a combination of two grades 
on a scale from 1 to 5 that represent the most common and second most 
common patterns of cellular differentiation in a given specimen.  
Although the introduction of PSA screenings has significantly 
improved the ability of detecting prostate malignancies, and the Gleason’s 
scoring system has provided for a systematic classifications of tumors 
based on their histological features, the current diagnostic procedures are 
far from optimal, and this is mainly due to two significant limitations. First, 
PSA serum level has been proven to lack specificity for a cancerous state 
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versus other pathological conditions of the prostate such as prostatitis and 
Benign Prostatic Hyperplasia (BPH) (Troyer et al., 2004; Reynolds et al., 
2007). It has been shown that only 25% to 35% of men with elevated PSA 
serum levels actually develop tumors (Smith et al., 1997). This high rate of 
false positives results in overdiagnosis and exposure of the patients to 
unnecessary risks and complications associated to invasive procedures 
(biopsies) and collateral effects of prostate cancer treatment (hormonal, 
radiation and surgical therapies). Second, a low Gleason score (2 to 6) is 
assigned to well differentiated cell populations and usually is indicative of 
a favorable prognosis, while a high Gleason score (8 to 10) is assigned to 
poorly differentiated cell populations and usually is indicative of an 
aggressive and recurrent disease. However, research on diagnostic 
methodologies for prostate cancer shows that up to 45% of biopsies in a 
given sample population are classified as Gleason 7 (Sim et al., 2007; 
Nguyen et al., 2009), for which the prognosis is extremely unpredictable. 
This situation translates into an inability to discriminate between patients 
that need intensive treatment or even to be enrolled in experimental 
clinical trials, from patients who do not need any therapy and would 
actually be harmed by the side effects related to any treatment. 
In this scenario, there was a great deal of effort in the past years to 
improve the tools that clinicians currently use for the diagnosis and risk 
assessment of prostate cancer, and particular attention has been given to 
the discovery of better diagnostic and prognostic biomarkers. By 
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extensively exploiting genomics, proteomics and bioinformatics 
techniques, the scientific community has identified and validated a set of 
biomarkers that bear a great potential for the improvement of current 
diagnostic procedures (Sardana et al., 2008; Makarov et al., 2008; Parekh 
et al., 2007). One of these markers is PCA3, a long non-coding RNA 
(ncRNA) transcribed from chromosome 9q21 (Bussemaker et al., 1999).  
Over the years, PCA3 has been extensively validated as a gene 
specifically up-regulated in prostate cancer and its diagnostic potential as 
a cancer biomarker has been established (Schalken et al., 2003; de Kok 
et al., 2002). The literature is constantly updated with reports on the 
applicability of PCA3 testing to a clinical setting and several diagnostic 
assays that rely on the detection of PCA3 in biological fluids have been 
developed (van Gills et al., 2007; de la Taille et al., 2007; Groskopf et al., 
2006). Approximately ten years of research on PCA3 led to the 
establishment of this gene as a bona fide prostate cancer biomarker, 
however, a function for such an important gene and its role in the biology 
of prostate cancer is yet to be uncovered. 
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1.6 Aims and Objectives 
 
To gain insight into the function of PCA3 and to identify 
corresponding antisense transcripts as yet unrecognized, we conducted a 
comprehensive analysis of partial cDNA sequences that flank PCA3 on its 
opposite DNA strand. At this genomic locus, we found a transcript that 
spans ~300kb and identified a human gene antisense to PCA3: PCA3 
Controlled - Tumor Suppressor Gene Candidate (PC-TSGC). We cloned 
and expressed two distinct splicing isoforms of PC-TSGC, and showed 
that expression of PC-TSGC is regulated by its intronic-antisense ncRNA 
PCA3 in human prostate cancer cells, data providing a potential function 
for this important biomarker. We prove that PC-TSGC encodes for a new 
protein that interacts with two partners: RhoA and nm23-H1, and 
demonstrate that decreased levels of PC-TSGC result in increased 
activation of AKT and ERK1/2 signaling pathways. Finally, our data show 
that PC-TSGC prevents anchorage-independent cell growth of prostate 
cancer cells, as well as tumor growth in vivo.  
Taken together, we propose for the first time a role for the PC-
TSGC and PCA3 interplay in the biology of human prostate cancer, and 
we show that these newly discovered PCA3- and PC-TSGC- mediated 
mechanisms yield insights and possible targets for therapeutic intervention 
in prostate cancer. 
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CHAPTER 2:  
IDENTIFICATION OF PC-TSGC 
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2.1 Analysis of chromosome 9q21 genomic region 
 
The ncRNA PCA3 (GenBank accession number: AF103907) is 
transcribed from chromosome 9q21 into several isoforms. The largest is 
4kb (Bussemakers et al., 1999) (Figure 2.1A). Two distinct mRNAs on 
both sides of PCA3 are transcribed from the opposite DNA strand, in an 
antisense orientation to PCA3 (Figure 2.1B). The mRNA located 
downstream to PCA3 is transcribed from a gene named PRUNE2 
(GenBank accession number: BC019095) (Strausberg et al., 2002), while 
the mRNA upstream to PCA3 has actually been assembled from several 
cDNA fragments and referred to as BMCC1 (BCH-motif-containing 
molecule at the C-terminal region 1, GenBank accession number: 
AB050197) (Machida et al., 2006). PRUNE2 and BMCC1 are annotated 
as full-length genes, and several mRNAs as well as spliced Expressed 
Sequenced Tags (ESTs) from the GenBank clearly align in 
correspondence to both sequences, marking the boundaries of their 
transcriptional start and end sites (Figure 2.1C).  In this location, we 
noticed one single EST (GenBank accession number: DA410068) (Kimura 
et al., 2006) that spans almost 140,000 base pairs, and specifically a 
genomic region including more than half of the PRUNE2 sequence, the full 
PCA3 sequence and the 5’ end of BMCC1 (Figure 2.1D), alternatively 
indicating that the BC019095 and AB050197 sequences could actually be 
part of a single transcriptional unit.  In this case, PCA3 would be then 
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transcribed from a genomic region that could be identified as an intron of a 
new gene not yet annotated. Recent studies have shown that among the 
overall expression of long ncRNAs in prostate cancer, a significant portion 
of these genes are transcribed from intronic regions in an antisense 
orientation to the corresponding sense gene (Louro et al., 2007). These 
observations reinforced our reasoning that the annotated sequences 
identifying PRUNE2 and BMCC1 are incomplete sequences that are 
instead part of a single transcriptional unit spanning ~300kb. In this case, 
such transcript would extend from the 5’ UTR region of PRUNE2 to the 3’ 
UTR region of BMCC1, covering a significant intronic region that includes 
PCA3 and therefore classifying PCA3 as a intronic-antisense ncRNA. 
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Figure 2.1 
 
Schematic representation of chromosome region 9q21.13 (not to 
scale). (A and B) Transcribed RNA sequences (black arrows) and exons 
(white boxes) are represented. Arrow heads indicate the orientation of the 
transcripts. (C) Representative ESTs correspond to the BC019095 and to 
the AB050197 sequences. (D) The EST DA410068 links the two EST 
clusters flanking PCA3. (E and F) Full-length PC-TSGC isoforms are 
shown: the alternative splice sites, are highlighted by red stars (missing 
exons) and by the green arrow (new exon). 
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2.2 Isolation and Cloning of PC-TSGC 
 
To verify the expression of this single transcript we designed 
several forward primers targeted along the BC019095 sequence 
(PRUNE2) and reverse primers targeted along the AB050197 sequence 
(BMCC1). We tested different combinations of forward and reverse 
primers on cDNA samples prepared from a variety of cell lines and tissue 
samples. In brief, we outlined RT-PCR experiments to amplify several 
regions of the putative full-length gene, resulting in size of amplicons 
ranging from 0.1kb up to 12kb, where a 12kb PCR product would match 
the full-length transcript.  To accomplish this, forward primers annealing to 
exon 1, exon 2, and exon 5 of PRUNE2 were used in combination with 
reverse primers annealing to exon 1, exon 2 and exon 13 of BMCC1. We 
screened by RT-PCR a panel of RNA samples from commercially 
available prostate cancer cell lines (LNCaP, PC3, DU145), lung cancer 
cell line (A549K), and glioma cell line (U87) considering that almost all of 
the ESTs aligning to either PRUNE2 or BMCC1 are derived from lung or 
brain tissues. In addition, we tested RNA of cell lines derived from other 
tissues such as kidney (HEK293) and soft tissue sarcoma (KS1767). 
Then, we included commercially available human RNA from prostate 
tumor as well as from other normal tissues (liver, kidney, breast, lung, 
pancreas, spleen and testes). Finally, we screened RNA extracted from 
human prostate tumor tissue samples and prostate tumor xenografts 
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models, including the MDA-PCa-118a, MDA-PCa-118b, and MDA-PCa-
133, which are prostate cancer tumor graft established at the David H 
Koch Center, The University of Texas M. D. Anderson Cancer Center.  
From this screening, we were able to obtain several RT-PCR 
products of the expected size from most of the screened cDNA samples, 
however the amplification of the full-length 12 kb cDNA fragment was 
accomplished only from a cDNA sample derived from the prostate cancer 
tumor graft MDA-PCa-133, by using a forward primer targeted to the very 
beginning of exon 1 of BC019095, and a reverse primer targeted to the 
very end of exon 13 of AB050197 (Appendix A, Table A.1) (Figure 2.3A). 
Next, we cloned the 12kb amplicon into a pCR2.1 TOPO-TA vector 
(Invitrogen). Restriction enzymes analysis and DNA sequencing of the 
cloned sequences confirmed that we were able to isolate two different 
isoforms that closely matched our 12 kb predicted sequence (Figures 2.1E 
and 2.1F). The alignment of both cloned sequences against the human 
reference genome assembly proved that such sequence is transcribed 
from a genomic locus harboring a single transcriptional unit that spans 
almost 300kb on chromosome 9q21 (Figure 2.2).   
Based on sequence analysis and functional characterization of the 
12 kb cloned sequences (presented in the following chapters), we named 
this new genetic unit “PCA3 Controlled – Tumor Suppressor Gene 
Candidate” (PC-TSGC). The sequences representing two different 
isoforms of PC-TSGC were entered into the GenBank as PC-TSGC1 
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(GenBank accession number: FJ808772, Appendix B.1) and PC-TSGC2 
(GenBank accession number: FJ808773, Appendix B.2) 
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Figure 2.2 
 
Identification and analysis of full-length PC-TSGC. Alignment of 
PC-TSGC1 and PC-TSGC2 full-length cloned sequences against the 
human reference genome assembly on the Genome Browser web server. 
PC-TSGC1 and PC-TSGC2 are indicated by red arrows. 
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2.3 Sequence analysis of PC-TSGC1 and PC-TSGC2 
 
Both PC-TSGC1 and PC-TSGC2 lack two exons at the 3’ region of 
the gene that instead are present in the BMCC1 transcript; moreover, in 
the same region, PC-TSGC2 includes a new exon that was never 
annotated in any EST. Finally, at the 5’ end of the gene, PC-TSGC2 is 
alternatively spliced resulting in the exclusion of exon 3 (Figure 2.1E and 
2.1F). All these features gain particular significance when an open reading 
frame (ORF) analysis is performed on both PC-TSGC1 and PC-TSGC2. 
PC-TSGC1 is the longer of the two isoform we identified (12,341 
nucleotides, Appendix B.1) and has a 9,174 nt open reading frame (ORF). 
In detail, following a relatively short 5’UTR (nucleotides 1 – 78), this ORF 
is in frame with a canonical Kozak sequence (GACATGG) (nucleotides 76 
- 82) containing the first Methionine start codon (nucleotides 79 – 81). 
Toward the 3’ region of the gene, a TAG stop codon is followed by a large 
3’ UTR (nucleotides 9,253 – 12,341). PC-TSGC1 translates for a predicted 
polypeptide of 3,057 residues.  
In the PC-TSGC2 isoform (12,217 nucleotides, Appendix B.2), 
alternative splicing of exon 3 causes a frame-shift at the 5’ region, while 
the novel exon at the 3’ region introduces an early stop codon. As a 
consequence, PC-TSGC2 displays a significantly larger 5’ UTR 
(nucleotides 1 – 409), and it exploits an alternative translation starting site 
where another canonical Kozak sequence (ACCATGG) (nucleotides 407 – 
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413) and first ATG codon are found in frame with the main ORF of 8,202 
nt. The early stop codon introduced by alternative splicing marks the 
boundary with an also larger 3’UTR (nucleotides 8612 – 12217). PC-
TSGC2 translates for a predicted truncated polypeptide of 2,733 residues.  
Analysis of conserved domains revealed a DHHA2 domain at the 
amino-termini of both PC-TSGC1 and PC-TSGC2, whereas PC-TSGC1 
additionally has an amino-terminal PPX1 domain and a carboxy-terminal 
BCH/Sec14p-like domain (Figure 2.3B).  
The DHHA2 domain stands for DHH Associated domain 2, and is 
often found adjacent to a DHH domain, which is a conserved domain 
characterized by a DHH motif (Aravind et al., 1998), however, we did not 
find any DHH domain in PC-TSGC1. The DHHA2 is diagnostic of DHH 
subfamily 2 members, which identifies a family of phosphoesterases 
responsible for the hydrolysis of phosphodiester bonds, including 3’,5’-
cyclic nucleotides (e.g. cAMP, cGMP) (Middelhaufe et al., 2007). This 
domain is about 120 residues long and contains a conserved DXK motif at 
its amino-terminus.  
The PPX1 region is an inorganic pyrophosphatase - 
exopolyphosphatase domain involved in energy production and 
conversion (Sutera et al., 1999), and the BCH/Sec14p-like region, here 
referred to as BCH, is generally found in lipid-regulated proteins such as 
RhoGAPs, RhoGEFs, and neurofibromin (Shang et al., 2003; Zhou et al., 
2002). The BCH domain of PC-TSGC1, is similar to the BCH domain 
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already described for the BMCC1 sequence (Machida et al., 2006), with 
the only difference of an in-frame 29 amino-acids deletion due to the 
absence of the two exons at the 3’ region of PC-TSGC1, when compared 
to BMCC1 (Figure 2.1E). Within the BCH domain of PC-TSGC1, a 
RRRMP motif (residues 2967-2971) corresponds to the RRKMP sequence 
known to be involved in homophilic/heterophilic interactions between BCH 
domain-containing proteins, and a conserved RRLRK motif (residues 
2985-2989) represents the arginine patch of BCH domains, which is 
necessary for the activity of a BCH domain as a GTPase Activating 
Protein (Low et al., 2000). By aligning the two PC-TSGC1 and PC-TSGC2 
isoforms, it is clear that not only PC-TSGC2 is truncated at the C-
terminus, but also this truncation corresponds exactly with the beginning 
of the BCH domain of PC-TSGC1 (Figure 2.3B).  
Finally, Machida et al. (2006) have identified a P-loop motif on the 
BMCC1 sequence, which we have also found present in both the PC-
TSGC isoforms that we cloned (GPGWSGKT, residues 2652-2659 in PC-
TSGC1 and residues 2474-2481 in PC-TSGC2). P-loops are usually found 
in ATP and GTP binding proteins and they have also been described to 
mediate the activity of pro-apoptotic proteins (Larisch et al., 2000; Saraste 
et al., 1990). 
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Figure 2.3 
 
Amplification and sequence analysis of the 12kb PC-TSGC cDNA. 
(A) RT-PCR from the MDA-PCa-133 tumor graft yields the full-length PC-
TSGC 12kb amplicon. (B) Location of the conserved domains identified on 
PC-TSGC1 and PC-TSGC2. 
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CHAPTER 3: 
ANALYSIS OF PC-TSGC EXPRESSION AND REGULATION
 39 
3.1 PC-TSGC expression in cell lines 
 
We analyzed the expression profile of PC-TSGC in a panel of 22 
cell lines derived from several human tissues (Chapter 6: Materials and 
Methods). We performed quantitative RT-PCR (qRT-PCR) experiments by 
assaying the expression levels of PC-TSGC at four different regions along 
the PC-TSGC mRNA (TSGst, TSGmid, TSGsk2, and TSGend) (Appendix 
A, Table A.1). High levels of expression of PC-TSGC were evident in cell 
lines derived from brain, breast, and prostate tumors, with the highest in 
the prostate cancer cell line LNCaP. In contrast, the other two most 
common prostate cancer cell lines (DU145 and PC3) did not show 
significant PC-TSGC mRNA levels (Figure 3.1). Thus, from this analysis 
we selected the LNCaP cell line as the optimal prostate cancer model for 
the further characterization of PC-TSGC in vitro. 
 
Next, we investigated whether PC-TSGC is translated into an 
actual protein as predicted by our sequence analysis. We assayed LNCaP 
cell extracts by immunoblot with an anti-PRUNE2 antibody recognizing the 
amino-terminal region of PC-TSGC: a band of high molecular mass, 
consistent with the predicted full-length PC-TSGC isoform (337-kDa), was 
observed (Figure 3.2A).  
In order to confirm that the protein detected was actually PC-TSGC, 
we cloned the PC-TSGC1 and PC-TSGC2 coding sequences into a 
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pcDNA expression vector (Invitrogen) in frame with a carboxy-terminal V5 
tag (Figure 3.2B). We assayed the expression of the recombinant proteins 
in a negative expression background (from PC3 cell line) by immunoblot 
and the recombinant PC-TSGC1 band matched the endogenous PC-
TSGC band from the LNCaP extract (Figure 3.2A). Notably, PC-TSGC2 
was detected only minimally by the anti-PRUNE2 antibody, but this 
isoform was reactive with the anti-V5 antibody, a result in complete 
agreement with the amino-terminal truncation of PC-TSGC2, which 
contains the epitope recognized by the anti-PRUNE2 antibody. This result 
confirms that PC-TSGC not only is transcribed and processed into a 
mRNA of 12kb, but also is translated into protein isoforms of 3,057 (PC-
TSGC1) and 2,733 (PC-TSGC2) residues, as predicted by our analysis.  
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Figure 3.1 
 
Expression of PC-TSGC in cell lines. The TSGst, TSGmid, 
TSGsk2, and TSGend qRT-PCR assays were targeted to four different 
regions encompassing the entire PC-TSGC full-length sequence 
(Appendix A, Table A.1). Relative expression levels were compared 
against a panel of standard endogenous controls (Chapter 6: Materials 
and Methods). 
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Figure 3.2 
 
PC-TSGC protein expression. (A) Full-length PC-TSGC was 
expressed by LNCaP cells and matched the predicted molecular mass of 
337-kDa. Recombinant PC-TSGC isoforms were detected by both anti-
PRUNE2 and anti-V5 antibodies in PC3. A GFP expression vector was 
used as negative control. (B) Schematic representation of PC-TSGC1 and 
PC-TSGC2 expression vectors. Both sequences were cloned into a 
pcDNA3.1-DEST vector bearing the CMV promoter and V5 and His tags.  
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3.2 Induction of PC-TSGC by growth factors stimulation 
 
To begin to understand gene expression and regulation, we asked 
whether the levels of PC-TSGC were affected by cell culture conditions. 
We tested LNCaP cells grown under starvation conditions followed by 
stimulation with a combination of growth factors (GF; Chapter 6: Materials 
and Methods). We monitored PC-TSGC levels by western blot at different 
time points and we found that LNCaP cells exhibited increased expression 
of PC-TSGC over time after stimulation with growth factors (Figure 3.3). 
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Figure 3.3 
 
Time course analysis of the expression of PC-TSGC in LNCaP 
cells. Cells are tested under starvation conditions (GF-) and after 
stimulation with a combination of growth factors (GF+) at the indicated 
serial time points. 
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3.3 Regulation of PC-TSGC by the ncRNA PCA3 
 
By identifying the full-length PC-TSGC transcript, we also 
demonstrated that PCA3 is an antisense ncRNA, and precisely, 
transcribed from an intron of PC-TSGC. Several lines of evidences 
suggest that intronic-antisense ncRNA can be involved in the regulation of 
expression levels of the corresponding sense gene (Faghihi et al., 2008; 
Scheele et al., 2007; Louro et al., 2007; Katayama et al., 2005; Munroe et 
al., 2006; Tasheva et al., 1995), therefore, we tested whether PCA3 would 
be able to regulate the expression of PC-TSGC. We specifically down-
regulated PCA3 by siRNA in LNCaP cell line and we monitored PC-TSGC 
expression by qPCR and immunoblot. As a control, we used a validated, 
non-targeting siRNA under the same experimental conditions.  
We monitored PC-TSGC expression levels by using five assays 
targeted to different regions along the PC-TSGC transcript (TSGst, 
TSGmid, TSGsk1, TSGsk2, and TSGend) (Appendix A, Table A.1). We 
found that upon reduction of PCA3, all PC-TSGC regions were 
significantly upregulated. All the assays returned similar levels of up-
regulation of the PC-TSGC mRNA (Figures 3.4A and 3.4B), thus by 
averaging the results from each single assay, we detected a 41% overall 
increase of PC-TSGC mRNA levels concomitant with a 44% decrease of 
PCA3 mRNA levels (t-test, p<0.001; Figure 3.5A).  
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This result was also confirmed by immunoblot, data indicating that 
variations in levels of PCA3 can ultimately influence levels of PC-TSGC 
protein in LNCaP cells (Figure 3.5B). 
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Figure 3.4 
 
Comparative qRT-PCR analysis of PC-TSGC levels in PCA3 siRNA 
samples. (A) PC-TSGC mRNA levels in the control samples (non-targeted 
siRNA) were set at 100%; the increased levels of PC-TSGC mRNA are 
shown as percentage increases tested at five different regions along the 
PC-TSGC sequence (Appendix A, Table A.1). (B) Statistical analysis 
(Student’s t-test) for increases in PC-TSGC mRNA upon PCA3 siRNA 
treatment of LNCaP cells. The numbers mapped to a schematic 
representation of the PC-TSGC gene indicate the transcript regions tested 
by qRT-PCR. 
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Figure 3.5 
 
Overall variation in PC-TSGC mRNA levels upon treatment of 
LNCaP cells with PCA3 siRNA. (A) PC-TSGC mRNA levels in the control 
samples (non-targeted siRNA) were set at 100%, and are shown as 
percentage increases in the PCA3 siRNA sample (t-test, p<0.001). (B) 
Immunoblot of the variation of PC-TSGC protein levels upon treatment of 
LNCaP cells with PCA3 siRNA. 
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CHAPTER 4: 
FUNCTIONAL CHARACTERIZATION OF PC-TSGC 
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4.1 PC-TSGC associates with both RhoA and nm23-H1 
 
To begin characterizing PC-TSGC, we undertook a sequence 
analysis-based approach for the identification of possible interacting 
partners. As already mentioned, we identified three specific conserved 
domain from the PC-TSGC sequence: the BCH domain at the carboxy-
terminus, and the PPX1 and DHHA2 domains at the amino-terminus.  
In an attempt to characterize the BCH domain of BMCC1, Soh et al. 
(2008), were not able to amplify in a single contig the entire BMCC1 
sequence, which was originally assembled in vitro from several cDNA 
fragments (Machida et al., 2006), although they were able to clone a 
shorter sequence that they named BNIP2XL (BNIP2 Extra Long). 
BNIP2XL is approximately 750 residues long and comprises the entire 
carboxy-terminus of BMCC1, including its BCH domain. Sho and 
coworkers extensively characterized the protein-protein interaction 
between the BCH domain of BNIP2XL and RhoA in cell lines transfected 
with two different recombinant isoforms of BNIP2XL (BNIP2XLα, which 
bears the full BCH domain similarly to BMCC1, and BNIP2XLβ, which 
bears a BCH domain harboring a 37 amino acids deletion at the carboxy-
terminus) and recombinant RhoA, a small GTPase involved in the 
formation of stress fibers and in the induction of oncogenic transformation. 
Importantly, they showed that BNIP2XL inhibits RhoA, via its BCH domain 
(Soh et al., 2008).  
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Sequence analysis of PC-TSGC shows that the full-length PC-
TSGC transcript (PC-TSGC1) includes both BMCC1 and BNIP2XL 
sequences and that the same BCH domain is found at its carboxy-
terminus, with the exception of an in-frame 29 amino acids deletions 
similar to the one reported for BNIP2XLβ (Figure 4.1A and 4.2A). Thus, it 
would be reasonable to predict that also the BCH domain of PC-TSGC 
could associate with RhoA. However, we wanted to test whether such 
interaction takes place between RhoA and the full-length PC-TSGC 
protein, and equally importantly, whether the interaction occurs between 
endogenous proteins.  
Endogenous PC-TSGC produced by LNCaP cells was 
immunoprecipitated and probed for endogenous RhoA. We tested LNCaP 
cells grown under starvation conditions followed by stimulation with a 
combination of growth factors (GF). Our results show that PC-TSGC is 
associated to RhoA upon cell stimulation in vitro (Figure 4.2B).  The 
association of PC-TSGC to RhoA upon cell stimulation with growth factors 
indicates that the observed interaction is specific and inducible.  
At the amino terminus instead, the presence of the PPX1 and the 
DHHA2 domains define a region of the protein that is similar to the protein 
hPRUNE. hPRUNE is a phosphodiesterase (PDE) belonging to the DHH 
superfamily of phosphoesterases and pyrophosphatases (D’Angelo et al., 
2004). This protein superfamily is characterized by the presence of four 
distinct motifs, among which the third one is the most conserved one and 
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contains the DHH sequence, from which the superfamily derives its name 
(Aravind et al., 1998). Both PC-TSGC and hPRUNE harbor the PPX1 and 
the DHHA2 domain, however PC-TSGC lacks the DHH motif (Figure 
4.2A).   
Despite this difference in the domain architecture and the fact that 
PC-TSGC extends significantly beyond this region, resulting in a 
polypeptide almost 7-times the size of hPRUNE, we found a high degree 
of similarity between the entire hPRUNE sequence and the amino 
terminus of PC-TSGC, including a region of hPRUNE that has been 
shown to mediate the interaction of hPRUNE with non-metastatic protein 
23 (nm23-H1) (Middelhaufe et al., 2007; Reymond et al., 1999) (Figure 
4.1B). Therefore, we tested whether PC-TSGC might also associate with 
nm23-H1. Immunoprecipitation analysis of the endogenous PC-TSGC 
confirmed that both PC-TSGC and nm23-H1 coimmunoprecipitate within 
the same complex (Figure 4.2B). Even in this case, we observed that such 
association is specific and inducible upon cell stimulation with growth 
factors. This results show that PC-TSGC has at least two protein partners, 
RhoA and nm23-H1, both of which play roles in the oncogenic 
transformation and metastatic potential of cancer cells (Coleman et al., 
2004, Hartsough et al., 2000). 
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Figure 4.1 
 
 Sequence alignment between PC-TSGC1 and RhoA and nm23-
H1. (A) Sequence alignment of the BCH domain from BNIP2XLα (full-
length domain), BNIP2XLβ (37 amino acid deletion), and PC-TSGC1 (29 
amino acid deletion in-frame). The sequences for the BCH domain are 
highlighted in red. (B) Sequence alignment of the carboxy-terminus of 
hPRUNE (residues 378-453) with the corresponding region in PC-TSGC1 
(residues 412-654): the sequence of hPRUNE known to mediate the 
interaction with nm23-H1 is highlighted in red.  
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Figure 4.2 
 
Association of PC-TSGC with RhoA and nm23-H1. (A) Hypothetical 
protein interactions with RhoA and nm23-H1: conserved domains are 
indicated in blue (PPX1), red (DHH and DHHA2), and green (BCH), and 
protein sequences are indicated in gray. (B) Co-immunoprecipitation of 
PC-TSGC with RhoA and nm23-H1. Lysates from LNCaP wild-type cells 
under starvation (GF-) or stimulated (10 minutes) with a combination of 
growth factors (GF+) were tested. The anti-PRUNE2 antibody efficiently 
immuno-precipitated (IP) endogenous PC-TSGC (IP:PC-TSGC – IB:PC-
TSGC); endogenous RhoA associated with PC-TSGC upon growth factors 
stimulation (IP:PC-TSGC – IB:RhoA); endogenous nm23-H1 associated 
with PC-TSGC upon growth factors stimulation (IP:PC-TSGC – IB:nm23-
H1); total cell extracts prior to IP used as loading controls confirmed that 
the observed associations were specific and inducible (Input – IB:RhoA;  
Input – IB:nm23-H1). 
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4.2 PC-TSGC participates in the control of anti-apoptotic 
and cell proliferation signaling pathways 
 
PC-TSGC interacts with RhoA and nm23-H1, and its primary 
sequence harbors features such as the BCH domain and the P-loop that 
are found in proteins involved in the regulation of cell proliferation and 
apoptosis (Low et al., 2000; Larisch et al., 2000).  
Because the levels of PC-TSGC increase upon down-regulation of 
PCA3 (Figures 3.4 and 3.5), we treated LNCaP cells with PCA3 siRNA, 
and monitored cell viability by using a metabolic assay with WST-1 
reagent (Roche). The WST-1 reagent measures the cleavage of a 
tetrazolium salt to formazan, which directly correlates to the number of 
metabolically active cells in the culture. Notably, we found that LNCaP 
cells treated with PCA3 siRNA were ∼20% less viable than control cells (t-
test, p<0.005; Figure 4.3), indicating a possible role for PC-TSGC in cell 
proliferation and/or apoptosis. To confirm this observation, we specifically 
down-regulated PC-TSGC in LNCaP by shRNA, and subsequently 
evaluated cell viability (Figure 4.4A). Consistently, we found that PC-
TSGC-shRNA cells were ∼20% more viable than control cells, both under 
starvation conditions (t-test, p<0.0001) and upon stimulation with a 
combination of growth factors (t-test, p<0.001) (Figure 4.4B).  
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Figure 4.3 
 
WST-1 metabolic assay on LNCaP cells treated with PCA3 siRNA. 
Cells are tested under four different conditions in vitro, with increasing 
concentrations of FBS: the highest reduction in cell viability is observed for 
cells cultured in media containing 2.5% FBS (∼20% reduction; t-test, 
p<0.005). 
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Figure 4.4 
 
Evaluation of the effect of PC-TSGC on cell viability. (A) Stable 
knock-down of PC-TSGC in LNCaP by puromycin selection of PC-TSGC-
shRNA cells. (B) WST-1 metabolic assay on PC-TSGC-shRNA cells 
compared with non-targeted control shRNA: differences were tested under 
starvation conditions (GF-; t-test, p<0.0001) and after stimulation with a 
combination of growth factors (GF+; t-test, p<0.001). 
 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
Next, we analyzed the phosphorylation status of AKT and ERK1/2, 
which are involved in the signal transduction of both anti-apoptosis and 
pro-proliferation pathways. Consistently with the cell viability assays 
results, we observed that both AKT and ERK1/2 were more activated in 
PC-TSGC-shRNA cells upon cell stimulation. Notably, the increased level 
of AKT phosphorylation was still appreciable in PC-TSGC-shRNA cells 
even if LNCaP cells are known to have high constitutive levels of AKT 
activation (Nesterov et al., 2001). Likewise, ERK1/2 phosphorylation 
status was remarkably higher in PC-TSGC-shRNA cells than control cells 
upon cell induction with growth factors (Figure 4.5). These results indicate 
that PC-TSGC is likely involved in the control of both anti-apoptotic and 
pro-proliferative signaling pathways. 
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Figure 4.5 
 
Effects of PC-TSGC on cell signaling transduction. Induction of 
ERK1/2 (pERK1/2: phosphorylated ERK1/2) and AKT (pAKT: 
phosphorylated AKT) signaling pathways by stimulation (10 minutes) with 
combination of growth factors (GF) in PC-TSGC-shRNA and control 
shRNA cells. 
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4.3 PC-TSGC prevents anchorage-independent cell growth 
 
To investigate whether PC-TSGC could play a role in the oncogenic 
transformation of prostate cancer cells, we performed a colony formation 
assay in semi-solid media (soft agar). The soft agar assay tests the ability 
of cells to grow without being attached to a solid surface (anchorage-
independency) and is one of the most stringent assays for cellular 
transformation in vitro. In fact, the phenotypic changes associated to the 
acquisition of an anchorage-independent phenotype closely resemble the 
same changes that occur during the neoplastic transformation of a cancer 
cell. 
With this experiment, PC-TSGC-shRNA cells grew extremely well 
in soft agar compared to the control (Figure 4.6A and 4.6B; t-test, 
p<0.0001), data indicating that a lack of PC-TSGC not only results in 
increased proliferation but also in anchorage-independent cell growth.  
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Figure 4.6 
 
Evaluation of the effect of PC-TSGC on anchorage-independent 
cell growth. (A) Colony count of PC-TSGC-shRNA cells and control cells 
following crystal violet staining. (B) Representative image of anchorage-
independent cell growth after PC-TSGC down-regulation.   
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4.4 PC-TSGC prevents tumor growth in vivo. 
 
To conclude our analysis, we finally tested whether PC-TSGC 
effect would also affect tumor growth in tumor bearing mice. We injected 
PC-TSGC-shRNA cells subcutaneously into SCID mice and then 
monitored tumor growth at up to three weeks in comparison with mice 
injected with control-shRNA cells. 
LNCaP cells have a very low efficiency rate of tumor formation in 
vivo. Remarkably, in our experiment we did not observe any tumor 
formation in the mice injected with control cells.  
Instead, mice injected with PC-TSGC-shRNA cells exhibited a 
striking difference in tumor growth, as 100% of mice formed tumors (t-test, 
p<0.04) (Figure 4.7). 
  
We demonstrate that a decrease in PC-TSGC levels leads to an 
increased activation of AKT and ERK1/2 signaling pathways, and the 
decrease in PC-TSGC confers an anchorage-independent phenotype and 
favors tumor formation and growth in vivo.  
Taken together, our results provide evidence that PC-TSGC has a 
role in determining the transformation and tumor growth potential of 
prostate cancer cells, and may be considered as a new tumor suppressor 
gene candidate. 
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Figure 4.7 
 
Evaluation of the effect of PC-TSGC on tumor growth in vivo. The 
tumor volumes of SCID mice injected subcutaneously with 5 million cells 
in a 50% volume of Matrigel were monitored at 2 and 3 weeks. PC-TSGC-
shRNA injected mice present significant tumor growth compared to 
control-shRNA injected mice (t-test, p<0.04).  
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CHAPTER 5: 
DISCUSSION 
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5.1 Identification of a new human gene: PC-TSGC 
 
Until now, PRUNE2 and BMCC1 were two distinct sequences that 
were annotated as independent genes on the opposite strand and in an 
antisense orientation to PCA3. Recent studies postulate the existence of a 
single transcript putatively comprising both PRUNE2 and BMCC1 and 
extending for approximately 300 kb (Clarke et al., 2009; Salagierski et al., 
2009). Such transcript was also predicted to be processed into a 12 kb 
mRNA, however, these studies were based on partial cDNA fragments, 
bioinformatics, and in silico sequence assembly (GenBank accession 
number: NM015225), without further genetic or functional data. With our 
work instead, we provide evidence for a new transcriptional unit on 
chromosome 9q21, which spans almost 300kb and includes a significant 
intronic region in correspondence to PCA3. This finding not only provides 
evidence for a previously unrecognized genetic element, but also at the 
same time allows classifying PCA3 as an intronic-antisense ncRNA.  
We named the newly discovered gene “PCA3 Controlled-Tumor 
Suppressor Gene Candidate” (PC-TSGC) and we identified two splicing 
isoforms, PC-TSGC1 and PC-TSGC2, which encode polypeptides of 
3,057 and 2,733 amino acids, respectively.  
We have shown that the expression of PC-TSGC is responsive to 
stimulation of cells with growth factors in a time-dependent manner. Given 
the negative effect of PC-TSGC on the viability of prostate cancer cells, 
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we hypothesize that after stimulation with growth factors, the cells express 
PC-TSGC, which in turn opposes cell growth and survival, thereby 
resulting in a negative-feedback loop on the activity of growth signaling 
pathways.  
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5.2 Biological role of PCA3 in Prostate Cancer 
 
We have also shown that levels of PC-TSGC are influenced by its 
intronic-antisense ncRNA PCA3. A decade of research on PCA3 has led 
to the establishment of this ncRNA as a bona fide prostate cancer 
biomarker; in fact, several diagnostic assays that rely on the detection of 
PCA3 in biological fluids have been developed (van Gills et al., 2007; de la 
Taille et al., 2007; Groskopf et al., 2006). Although the importance of 
testing for PCA3 in human prostate cancer-related applications is widely 
available (www.pca3.org), a function for this ncRNA and its role in the 
biology of prostate cancer has not as yet been described. Here, we have 
shown (i) that levels of PC-TSGC increase upon down-regulation of PCA3, 
and (ii) that PCA3 down-regulation is associated with a decrease in cell 
viability, which could be a consequence of the concomitant increase in 
PC-TSGC. In mammalian cells, only a handful of examples of gene 
regulation by ncRNA have been reported to date, and mechanistic insights 
of their function remain largely unknown (Faghihi et al., 2009). PCA3 is a 
fully intronic, antisense, and spliced ncRNA, which is perhaps one of the 
least characterized classes of long ncRNA. Our siRNA data demonstrate 
that PCA3 regulation over PC-TSGC is specifically mediated by the actual 
PCA3 transcript, rather than occurring via sense-antisense transcriptional 
interference. 
 80 
Considering the possible molecular mechanisms of gene 
expression regulation by antisense long ncRNA, it is very unlikely that 
PCA3 as a ncRNA could elicit chromatin modifications or promoter 
methylation that would in turn shut down the expression of PC-TSGC. In 
fact, these kind of epigenetic regulations are usually mediated by 
antisense ncRNAs that are located in the proximity of the promoter of the 
corresponding sense gene (Faghihi et al., 2008; Scheele et al., 2007; 
Munroe et al., 2006). Furthermore, any DNA methylation or chromatin 
remodeling would drastically impair the transcription of both PC-TSGC as 
well as PCA3, which is a condition that is not compatible with our 
experimental observations. Therefore, because we show that PCA3 and 
PC-TSGC are simultaneously expressed at different levels in LNCaP cells, 
and because we demonstrate an inverse correlation between the RNA 
level of both genes, we hypothesize that the PCA3 regulation over PC-
TSGC likely depends on the formation of a PCA3:PC-TSGC nuclear RNA 
duplex, which may affects the transport, and/or stability of PRUNE2 
primary transcripts in prostate cancer cells.  
PCA3 is mainly localized in the nucleus (Schalken et al., 2003) but 
most importantly, is fully intronic to PC-TSGC. Because PCA3 does not 
overlap with any intron-exon junction of PC-TSGC, we would exclude a 
potential regulation of PCA3 of the alternative splicing of PC-TSGC. 
Instead, a likely regulatory function of PCA3 could involve an RNA editing-
mediated mechanism that would affect PC-TSGC stability and/or nuclear 
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localization. This mechanisms would depend on the recognition of the 
PCA3:PC-TSGC RNA nuclear duplex by the RNA editing enzyme ADAR1 
(Keegan et al., 2004). According to the degree of RNA editing, the PC-
TSGC RNA would then face different fates, including sequestration in the 
nucleus and/or subsequent degradation. 
PCA3 presents multiple transcriptional start sites as well as 
polyadenylation sites, and the complexity of its transcriptome renders the 
identification of a precise mechanism of action a challenging task. 
However, to our knowledge, this report is the first demonstration of a 
biological function for the ncRNA PCA3 towards the regulation of PC-
TSGC and cellular viability in prostate cancer.  
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5.3 Biological role of PC-TSGC in Prostate Cancer 
 
We have also shown that sequence analysis and functional assays 
in human LNCaP cells confirm that PC-TSGC affects cell viability, and that 
a decrease in PC-TSGC results in anchorage-independent cell growth and 
tumor formation in vivo.  These represent possible mechanisms potentially 
linked to the protein interaction of PRUNE2 with RhoA and nm23-H1.  
 
A detailed work of characterization performed by Soh and 
coworkers on the BCH domain of BNIP2XL demonstrate that this domain 
is able to interact and inhibit RhoA in human cell lines. This process 
includes the sequestration of RhoA and the inhibition of its binding to the 
Lbc-RhoGEF, which is the specific guanine exchange factor (GEF) 
responsible for RhoA activation (Soh et al., 2008). We demonstrated that 
endogenous PC-TSGC and RhoA specifically interact upon cell 
stimulation by growth factors. Considering that BNIP2XL is almost 
identical to the caboxy-terminus of the full-length PC-TSGC protein, and 
that a lack of PC-TSGC results in increased cell proliferation, it can be 
assumed that PC-TSGC may exert its function at least in part by 
preventing the binding of RhoA to its activator Lbc-RhoGEF. However, 
since the BCH domain has been shown to possess a GTPase activating 
protein (RhoGAP) function (Shang et al., 2003), we cannot exclude that 
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PRUNE2 could also directly promote hydrolysis of GTP by the GTP-bound 
RhoA, directly terminating any downstream RhoA signaling.  
RhoA signaling induces, via distinct pathways, the phosphorylation 
of both ERK1/2 and AKT (Del Re et al., 2008; Basile et al., 2007; Coleman 
et al., 2004). In particular, the expression of RhoA stimulates cell cycle 
progression and proliferation by inducing the G1/S phase transition in 
quiescent cells (Olson et al., 1995). Several mechanisms have been 
suggested for such function, including the repression of CDK inhibitors 
such as p21 and p27, or the induction of cyclinE/CDK2, and in general, an 
active RhoA signaling is required for a sustained activation of the ERK 
signaling pathway, which eventually leads to the progression through the 
G1 to the S phase (Coleman et al., 2004).  At the same time, RhoA 
modulates cell fate and survival by engaging a signaling pathway through 
focal adhesion kinase (FAK). Activation of FAK leads to activation of PI3K 
and concomitant phosphorylation of AKT (Del Re et al., 2008). 
Our experiments with shRNA show that cells that lack PC-TSGC 
exhibit enhanced rates of cell viability, a condition confirmed by an 
increased activation of both ERK1/2 and AKT signaling pathways. Given 
the RhoA-inhibitory properties of the BCH domain (Soh et al., 2008), it is 
possible that decreased levels of PC-TSGC lead to more sustained RhoA 
signaling, therefore resulting in increased cell viability. 
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On the other hand, we found common conserved domains between 
the amino-terminus of PC-TSGC and the protein hPRUNE, which is able 
to interact and inhibit nm23-H1 in breast cancer. We demonstrated that 
PC-TSGC is also able to interact with nm23-H1 upon stimulation with 
growth factors, however the interaction of PC-TSGC with nm23-H1 leaves 
more open questions.  
hPRUNE is the human homologous of the Drosophila PRUNE 
protein which was first described for the brownish eye color phenotype of 
PRUNE mutant flies (Galasso et al., 2009; Lifschytz et al., 1969). The 
Drosophila PRUNE protein is known to interact with the awd (abnormal 
wing disc) gene family, whose human homologous proteins are known as 
the nm23 gene family (Timmons et al., 1995). Nine different proteins have 
been described for this family, coding for proteins with anti-metastatic 
properties. In humans, hPRUNE is able to interact and to inhibit nm23-H1 
and this inhibition results in increased motility and metastatic potential for 
breast cancer cells (D’Angelo et al., 2004). nm23-H1 is well-known for 
preventing metastasis formation in certain type of cancers, however it is 
not yet clear how exactly nm23-H1 exerts this function (Galasso et al., 
2009). The nm23 proteins have several known biochemical activities: as 
nucleoside diphosphate kinase (NDPK), as phosphotransferase and 
histidine protein kinase, as a 3’-5’-exonuclease, and as a regulator of GTP 
binding proteins by direct interaction with guanine exchanging factors 
(GEF) activators. However none of these functions has been shown to be 
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essential and directly correlated to nm23 anti-metastatic activity. In 
addition, low levels of nm23-H1 have generally been correlated with more 
aggressive tumors, but only in certain types of cancers (e.g., breast, 
melanoma, sarcoma and colon), whereas for others (e.g., neuroblastoma 
and Hodgkin lymphoma) the opposite correlation has been observed 
(Hartsough et al., 2000). The biological significance of this complex 
expression profile is not understood; particularly in regard to prostate 
cancer, the ultimate effect of the expression of nm23-H1 in the prostatic 
tumor is still controversial.  
For instance, several reports have associated the expression of 
nm23-H1 in prostate cancer with both anti-metastatic and anti-proliferative 
properties, whereas others have linked it to an increased malignant 
potential and aggressiveness of prostate cancer cells (Kim et al., 2003; 
Lee et al., 1999; Igawa et al., 1994; Konishi et al., 1993). In this scenario, 
the interaction of PRUNE2 with nm23-H1 raises several challenging 
questions due to the controversy surrounding the multiple biological 
functions of nm23-H1 and its role in different type of cancer.  
In this context, several nm23 protein family members interact with 
and inhibit guanine-exchange factor (GEF) activators for GTP-binding 
proteins. In particular, nm23-H1 inhibits Tiam1, a Rac-specific GEF 
(Miyamoto et al., 2009; Otsuki et al., 2001). One might indeed speculate 
that, through the RhoA-inhibitory action of its BCH domain, and the 
recruitment of nm23-H1 that in turn inhibits a specific Rac activator, 
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PRUNE2 could perhaps orchestrate a combined action towards the down-
regulation of different Rho-GTPase family members (RhoA and Rac), thus 
preventing oncogenic transformation of prostate cells as well as inhibiting 
tumor growth (Figure 5.1). 
The working model proposed in Figure 5.2 summarizes the findings 
presented in this thesis, and proposes a novel mechanism of action that 
involves PCA3 and PC-TSGC in the tumorigenesis process of prostate 
cancer cells.  
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Figure 5.1 
 
Proposed mechanism of action of PC-TSGC toward the 
downregulation of signal transduction of Rho GTPase family members. 
PC-TSGC inhibits the binding of RhoA to its activator Lbc-RhoGEF by 
direct interaction with RhoA through the BCH domain, and recruits nm23-
H1 which in turn inhibits Tiam1, a specific Rac activator. GEF: Guanine 
nucleotide Exchange Factor; GAP: GTPase Activating Protein.   
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Figure 5.2 
 
Proposed biological roles of PCA3 and PC-TSGC in prostate 
cancer. (A) Normal cell: growth stimuli are signaled to the nucleus through 
multiple pathways that include activation of RhoA and Rac and 
subsequent phosphorylation of AKT and ERK1/2. The signal transduction 
cascade stimulates gene expression in order to initiate cellular replication 
and inhibit apoptosis. Simultaneously, the same signals elicit the 
expression of PC-TSGC which in turn inhibits RhoA and Rac (through 
nm23-H1), thereby resulting in a negative-feedback loop on the activity of 
cell growth signaling pathways. (B) Cancer cell: in a malignant cell, the 
same mechanism is altered by the abnormal expression of PCA3, which 
opposes the expression of PC-TSGC. As a result, the control over the 
RhoA and Rac signaling pathways is lost, and the cell engages an 
unregulated cell growth that potentially leads to oncogenic transformation. 
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5.4 General implications and conclusions 
 
With this work, we identified, cloned, and characterized PC-TSGC 
as a new tumor suppressor candidate, and we showed that PC-TSGC is 
regulated by its intronic-antisense ncRNA PCA3. These findings, aside 
from describing for the first time a new human gene as well as a biological 
role for the ncRNA PCA3 in prostate cancer, have also more general 
implications in cancer biology, providing a link between tumor suppression 
mechanisms and the RNA world.  
Cancer is a complex genetic disease that involves the activation of 
oncogenes and the inactivation of tumor suppressor genes. At the same 
time, ncRNAs are also involved in several complex genetic diseases, 
including cancer.  
The recognized mechanism of tumor suppression inactivation are 
based on both genetic and epigenetic mechanisms, including promoter 
methylations, chromatin remodeling, point mutations and loss of 
heterozygosity, homozygus deletions, and mono- or bi-allelic mutational 
inactivations. In addition to these established mechanisms, with the results 
reported in this thesis we describe the interplay between the ncRNA PCA3 
and the tumor suppressor candidate PC-TSGC. Such interplay proposes 
the existence of another possible mechanism of tumor suppression 
inactivation that is based on down-regulation mediated by a ncRNA. 
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The translational and clinical implications of our findings are also 
relevant. First, PC-TSGC could be explored as a new prostate cancer 
biomarker. By further analyzing its expression in tumor tissue samples it 
would be interesting to evaluate any correlation between PC-TSGC 
expression levels and prostate cancer clinical outcomes. Second, PC-
TSGC should be regarded as a possible tool to be employed in the gene 
therapy of prostate cancer. Even though the size of PC-TSGC would 
introduce some restrains in the choice of a suitable gene therapy vector 
for its delivery, the striking tumor suppression potential of PC-TSGC 
renders this new gene an interesting candidate for such therapeutic 
approach. Third, we have uncovered new protein-protein interactions that 
propose new pathways involved in prostate cancer initiation and 
progression. Such pathways could be identified as new targets for the 
development of novel therapeutic strategies in the fight against prostate 
cancer. 
 
 
  In conclusion, this is the first report on the full characterization of 
PC-TSGC and PCA3 genes, and it identifies PC-TSGC as a new tumor 
suppressor gene candidate that is down-regulated by a ncRNA in prostate 
cancer cells.  We provide evidence that the regulation of cell growth in the 
prostate might be subject to fine-tuning that balances the expression and 
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activity of PCA3 and PC-TSGC to ensure cellular homeostasis. A 
disruption of this regulation could play a functional role in human prostate 
cancer.   
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CHAPTER 6: 
MATERIALS AND METHODS 
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6.1 Bioinformatics and sequence analysis 
 
Chromosomal locations, annotated transcripts, spliced ESTs and 
sequence mapping were visualized on the Genome Browser web server 
(genome.uscs.edu). Conserved domain analysis was performed on the 
NCBI website (www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi), and 
sequence alignments, with the ClustalW software 
(www.ebi.ac.uk/clustalw). 
 
 
 
6.2 Development of the prostate cancer tumor graft, MDA-
PCa-133 
 
 MDA PCa 133 tumor graft was developed by the prostate cancer 
biological models facility (David Koch Ctr. for Applied Research in 
Genitourinary Cancers) at the University of Texas, MD Anderson Cancer 
Center. Human tissue specimen used to developed MDA PCa 133 tumor 
graft was residual from surgery of a bone metastasis of a prostate cancer 
that was undergoing castrate resistant progression. Small pieces of the 
human prostate cancer were implanted into subcutaneous pockets of 6- to 
8-week-old male CB17 SCID mice (Charles River Laboratories). Tumor 
developed within 6 months of implantation and was maintained by 
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passage through mouse as the cells did not sustain in vitro growth. Written 
informed consent had been obtained from the patient before sample 
acquisition and sample was processed according to a protocol approved 
by our institutional review board.   
MDA-PCa-133 tumor graft has high expression of Prostate Serum 
Antigen (PSA).  
 
 
 
6.3 Cell lines and cDNA samples 
 
All human cell lines (n=22) of our panel (LNCaP, PC3, DU145, SF-
268, SF-539, SNB-75, U-87, BT-549, Hs587T, MCF-7, NCI-ADR-RES, 
NCI-H322M, A549K, EKVX, NCI-H266, SK-MEL-28, UACC-257, OVCAR-
8, SK-OV-3, ACHN, HEK293, TK-10) were cultured in RPMI containing 
5% Fetal Bovine Serum (FBS). Total RNAs from cell lines were isolated 
with the RNeasy mini kit (Qiagen, Hilden, Germany) or the Norgen All-in-
One Purification kit (Norgen Biotek Corp, Thorold, ON, Canada). Total 
RNAs from human tissue samples (prostate, brain, liver, kidney, breast, 
lung, pancreas, spleen, and testis) were purchased from Stratagene (La 
Jolla, CA, USA). Total MDA-PCa-133 RNA was obtained from an early 
passage of the prostate cancer tumor graft MDA-PCa-133. cDNAs were 
synthesized with Superscript III reverse transcriptase (Invitrogen 
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Corporation, Carlsbad, CA, USA) from 1µg of total RNA, with N15 random 
pentadecamers or oligo dT primers.   
 
 
 
6.4 DNA Cloning 
 
The sequences of all oligonucleotide primers used are presented 
(Appendix A, Table 1). Full-length PC-TSGC was amplified from the MDA-
PCa-133 cDNA with the KAPA HiFi DNA polymerase (KAPA Biosystems, 
Cambridge, MA, USA). The isolated band was gel-purified, cloned into 
TOPO-TA pCR2.1 (Invitrogen), and sequenced. Next, PC-TSGC1 and 
PC-TSGC2 coding sequences were re-amplified and subcloned into a 
pENTER/D-TOPO cloning vector (Invitrogen).  Finally, each coding 
sequence was inserted into a pcDNA-DEST40 expression vector in frame 
with V5 and His tags, by the use of the Gateway recombination technology 
(Invitrogen).  Each cloning step was confirmed by DNA sequencing and 
restriction enzyme mapping.  
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6.5 Quantitative RT-PCR 
 
qRT-PCR analysis were performed in a Fast-7500 Real Time PCR 
system with SYBR-green (Applied Biosystems, Foster City, CA, USA). 
Gene expression levels were normalized against three different standard 
endogenous controls (P0 large ribosomal protein (RPLP0), beta-
glucuronidase (GUSB), and TATA box-binding protein (TBP)) (Appendix 
A).  Relative expression levels were analyzed according to the ΔΔCt 
method (Livak et al., 2001).  
 
 
 
6.6 Transfections and Western blot analysis 
 
PC-TSGC1 and PC-TSGC2 were transfected into PC3 cells with 
the FugeneHD transfection reagent (Roche, Indianapolis, IN, USA). 
Transgene expression was tested 72 hours after transfection. A GFP-
pcDNA3.1 construct was used as a negative control.   
Total cell protein extracts were prepared with the Norgen All-in-One 
Purification kit and were normalized according to the BCA protein assay 
(Pierce, Rockford, IL, USA). One to 5 µg of protein was loaded onto a 4-
12% bis-Tris NuPAGE gel (Invitrogen); proteins were resolved and were 
subsequently blotted on a nitrocellulose filter (BioRad, Hercules, CA, 
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USA). PC-TSGC isoforms were detected with an anti-PRUNE2 antibody 
(ProteinTech Group, Inc, Chicago, IL, USA) or an anti-V5 antibody 
(ABcam, Cambridge, MA, USA). Antibodies against total-AKT, phospho-
AKT, total ERK1/2, and phospho-ERK1/2 (Cell Signaling Technology, 
Beverly, MA, USA) were used to analyze signaling function. Endogenous 
levels of actin were monitored with a horseradish peroxidase-conjugated 
anti-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as a 
loading control for each blot. 
 
 
 
6.7 Cell induction 
 
Subconfluent LNCaP cells were starved for 24 h in RPMI containing 
0.25% bovine serum albumine (BSA), and then induced with a 
combination of growth factors to final working concentrations of VEGF (10 
ng/ml), FGF (10 ng/ml), EGF (10 ng/ml), IGF (10 ng/ml), and 
supplemented with Heparin (5 units/ml).  
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6.8 Small interfering RNA and short hairpin RNA 
 
A custom-ordered Silencer Select siRNA against PCA3 (5’-
GGTTATACTTACTAGCACA-3’) (Ambion, Austin, TX, USA) was 
transfected with the NeoFX transfection reagent (Ambion) into LNCaP 
cells at a final concentration of 10nM. PCA3 knock-down was assayed by 
qRT-PCR 72 hours after transfection. For stable PC-TSGC knock-down, a 
pLKO.1 lentiviral vector expressing a shRNA against PC-TSGC (5’-
GCTCAGGGTTTAAGTATTGAA-CTCGAG-
TTCAATACTTAAACCCTGAGCT-3’) (Open Biosystems, Huntsville, AL, 
USA) was amplified and co-transfected into 293FT cells with 
Lipofectamine 2000 (Invitrogen), together with a third generation lentiviral 
packaging mix. Lentiviruses were produced and used to infect sub-
confluent LNCaP cells. Stable clones were maintained under puromycin 
selection (10µg/ml). Validated non-targeting siRNA (Ambion) or shRNA 
(Open Biosystem) were used as negative controls. 
 
 
 
6.9 Co-immunoprecipitation 
  
Subconfluent LNCaP wild-type cells grown in 10 cm dishes were 
starved for 24 hours and were subsequently induced for 10 minutes with 
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the combination of growth factors. Cells were washed with ice-cold PBS 
and lysed in 1% NP-40, 50 mM Tris-HCl, 135 mM NaCl, 1 mM EDTA, 1 
mM β-glycerol-phosphate supplemented with anti-protease (Complete-
Mini tablets, Roche) and anti-phosphatase (PhoSTOP tablets, Roche) 
mixes. Extracts were normalized with the BCA protein assay (Pierce) and 
were incubated overnight with 2µg of anti-PRUNE2 antibody (ProteinTech 
Group, Inc) containing 1% BSA. Lysates were incubated with protein A-
agarose (4 hours) and the immunocomplexes were washed and resolved 
on a 4-12% bis-Tris NuPAGE gel (Invitrogen).  Blotted filters were probed 
with anti-PRUNE2, anti-RhoA (Abcam), and anti-nm23 (Abcam) 
antibodies. Total cell extracts collected from each lysate prior to the 
immunoprecipitation step were also resolved on the same gel, probed, 
and used as loading controls (input).  
 
 
 
6.10 Cell viability assay  
 
Starved LNCaP cells were transfected in serum-free media with 
PCA3 siRNA oligos. Serial concentrations of FBS were added after 6 h. 
Cell viability was measured 72 h later by WST-1 cell viability reagent 
(Roche). PC-TSGC-shRNA LNCaP cells (or control) were starved for 24 h, 
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and then stimulated with the combination of growth factors. Cell viability 
was measured by WST-1 72 h later.  
 
 
 
6.11 Soft agar assay 
 
PC-TSGC-shRNA LNCaP cells and control cells were counted and 
resuspended in 1.5 ml of 0.35% agarose in growth medium, and seeded in 
6-wells dishes (5000 cells/well) previously filled with 1ml of 0.7% basal 
agarose in growth medium. Another layer of 0.7% agarose in growth 
medium was then added and cells were fed once per week. After 3 weeks, 
pictures were taken with an inverted microscope at 4x magnification, and 
colonies were stained with 0.005% crystal violet, and counted.    
 
 
 
6.12 Tumor formation assay  
 
PC-TSGC-shRNA LNCaP cells and control cells were counted and 
resuspended to a final concentration of 5 million cells in 100µl of PBS. 
Cells were then mixed in 50% volume of Matrigel and a total of 200µl of 
resuspended cells were then injected subcutaneously in the flank of 7-
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weeks old male SCID mice (Charles River). Tumor growth was monitored 
weekly, and tumor volumes were measured at two and three weeks from 
injection. 
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APPENDIX A 
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Table A.1 
 
List of primers used for qRT-PCR analysis and cloning of full-length 
PC-TSGC isoforms. 
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Primer name Task Sequence (5’  3’) 
TSG.fw ACCCCGCTCGTCTTCCTT 
TSG.rv 
Full-length PC-TSGC 
amplification CCAAAACGAAGTCTAACAGACA 
   
TSG1enter.fw CACCATGGAAGAATTTTTGCAACG 
TSG1enter.rv AGGCTTTTCTTTCAGCTTCAAGTC 
TSG2enter.fw CACCATGGAATCAGAGAAGATCTCAG 
TSG2enter.rv 
PC-TSGC1 and  
PC-TSGC2 coding 
sequences sub-cloning 
GAGAAGGTTACCTGAATCTCCTCC 
   
TSGst.fw CCACGACATGGAAGAATTTTTG 
TSGst.rv GCGTTTGCTTCGATTCAGTTT 
TSGmid.fw GGAGACCCAGTTCAGTGCTC 
TSGmid.rv TGTAAATGCTTTCAAGTCACTGGT 
TSGsk1.fw CGTTTATTTGCCGGTAGGAG 
TSGsk1.rv GCTCAGGCTCTTTGGTAGGA 
TSGsk2.fw GGGAAATGCTTTCACCACAG 
TSGsk2.rv CTCTTCAAAGGGGATGTCCA 
TSGend.fw TCAATAGCTTATCAGAACTCAGTGG 
TSGend.rv 
PC-TSGC qPCR assays 
TCAACAGAACCATGAACCAGA 
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Primer name Task Sequence (5’  3’) 
RPLP0.fw CGCTGCTGAACATGCTCAAC 
RPLP0.rv ATTGTCGAACACCTGCTGGAT 
GUSB.fw TGATCGCTCACACCAAATCC 
GUSB.rv CCTTGTCTGCTGCATAGTTAGAGTTG 
TBP.fw CCACAGTGAATCTTGGTTGTAAACTT 
TBP.rv 
Endogenous controls  
qPCR assays 
AAACCGCTTGGGATTATATTCG 
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APPENDIX B 
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B.1 PC-TSGC1 (GenBank accession number: FJ808772) 
 
 
Total bp: 12,341 
5’ UTR: 78 bp (1 – 78) 
Kozak sequence: 76 – 82 
ATG: 79 – 81 
Coding Sequence (in blue): 9174 bp (79- 9252) 
Stop codon: 9250-9252 
3’ UTR:  3089 bp (9253 – 12341) 
 
 
Full-length cDNA sequence: 
 
ACCCCGCTCGTCTTCCTTGGGCCGAGATTTTCCACTGCGCCCCTCCGAGTACCC
GGGTTCCAAACCCCTAGCCACGACATGGAAGAATTTTTGCAACGCGCCAAATCT
AAACTGAATCGAAGCAAACGCTTGGAGAAGGTCCATGTGGTTATTGGGCCTAAA
TCGTGTGACTTGGATTCTCTCATTTCTACCTTCACATATGCTTACTTTCTAGAC
AAGGTCAGTCCACCAGGGGTTCTGTGTTTACCAGTGCTGAACATACCAAGAACT
GAATTCAACTACTTCACCGAGACGAGGTTTATTTTAGAAGAGCTAAATATTTCC
GAATCATTCCACATATTCCGGGATGGAATTAACCTGCATCAGCTAAATGATGAA
GGGAAGTTATCGATAACACTTGTTGGCAGCAGTGTGCTGGCGAGTGAAGACAAA
ACTTTAGAATCAGCAGTTGTCAAAGTCATTAATCCGGTTGAGCAGAGCGATGCC
AACGTTGAGTTCCGAGAGTCTTCCTCTTCTCTCGTGCTAAAGGAGATTCTCCAA
GAGGCTCCTGAGCTCATCACCGAGCAACTGGCTCATCGCCTCAGAGGTAGCATT
CTTTTCAAGTGGATGACCATGGAATCAGAGAAGATCTCAGAGAAGCAGGAGGAA
ATTCTTTCTATCCTGGAAGAAAAATTTCCTAACTTGCCTCCAAGAGAGGACATC
ATCAACGTCCTACAGGAGACCCAGTTCAGTGCTCAGGGTTTAAGTATTGAACAG
ACAATGTTGAAAGATCTAAAGGAGCTGTCAGATGGAGAAATAAAAGTGGCCATT
AGTACTGTGAACATGAACCTTGAGAATTGTCTATTTCACAGCAATATTACCAGT
GACTTGAAAGCATTTACAGACAAGTTTGGTTTTGATGTCCTCATCCTGTTCTCC
AGCTATCTGTCAGAGGAGCAGCAGCCGAGACGACAGATTGCTGTGTACTCAGAA
AACATGGAGCTGTGCAGTCAGATTTGCTGTGAGCTGGAAGAGTGTCAGAACCCT
TGCCTAGAACTGGAGCCCTTTGACTGTGGCTGTGATGAGATCCTGGTGTACCAA
CAAGAGGACCCTTCAGTGACTTGTGATCAGGTGGTTCTCGTTGTCAAGGAAGTC
ATCAACAGGAGGTGTCCAGAGATGGTCTCCAATAGCCGGACATCCTCAACAGAA
GCCGTGGCAGGCAGTGCCCCCCTCTCCCAGGGGTCTTCTGGGATTATGGAATTG
TATGGTTCTGACATAGAGCCACAACCCAGCTCTGTGAATTTCATAGAGAACCCT
CCAGATCTCAATGATTCTAACCAGGCTCAGGTGGATGCCAATGTAGACCTTGTT
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AGCCCAGACAGCGGACTGGCTACCATTAGGAGCAGCCGCTCATCCAAGGAGAGC
TCTGTTTTCCTCAGTGACGACAGCCCCGTGGGAGAAGGTGCTGGGCCTCACCAC
ACCCTTCTCCCAGGGCTTGACTCCTACAGCCCCATCCCTGAAGGGGCGGTAGCG
GAGGAACATGCATGGTCTGGAGAACACGGTGAGCACTTCGACCTCTTCAATTTT
GACCCAGCACCCATGGCTTCTGGGCAGTCCCAGCAATCTTCTCATTCTGCAGAC
TACTCCCCAGCAGATGACTTCTTCCCCAACAGCGACCTGTCAGAAGGACAGCTC
CCCGCTGGGCCTGAAGGACTTGATGGCATGGGAACCAACATGTCTAATTATTCA
TCCAGTTCACTTTTGTCAGGGGCTGGCAAAGATAGCCTTGTGGAACATGATGAG
GAGTTTGTCCAGAGACAAGACAGTCCCAGAGATAACTCTGAAAGAAATTTGAGC
CTGACAGATTTTGTGGGAGATGAATCCCCTTCCCCAGAAAGGCTAAAAAATACT
GGAAAGAGGATCCCACCAACACCCATGAATAGTTTAGTAGAAAGCTCGCCATCC
ACTGAAGAACCAGCCTCACTCTATACCGAAGATATGACCCAAAAAGCAACTGAC
ACAGGTCACATGGGGCCACCTCAGACCCATGCACGGTGCAGCAGCTGGTGGGGT
GGTTTGGAAATTGACTCCAAAAATATTGCAGATGCGTGGAGTTCCAGTGAACAG
GAATCTGTTTTCCAGAGCCCTGAATCATGGAAAGAGCATAAGCCAAGCTCCATT
GATAGGAGAGCCTCAGATTCTGTATTTCAACCAAAGAGCCTCGAATTTACAAAG
TCAGGTCCCTGGGAGTCTGAATTTGGTCAGCCTGAACTGGGTAGCAATGATATT
CAAGACAAAAATGAGGAAAGCTTGCCGTTCCAGAACCTGCCCATAGAGAAGTCA
CCTTTGCCAAATACATCTCCCCAAGGAACAAACCACCTGATAGAAGACTTTGCT
TCTTTGTGGCATTCTGGTCGCTCTCCCACAGCCATGCCCGAGCCCTGGGGAAAT
CCTACAGATGATGGTGAACCAGCAGCTGTGGCGCCATTCCCAGCCTGGAGTGCA
TTTGGTAAAGAAGATCATGATGAAGCTTTAAAAAATACCTGGAATTTGCACCCA
ACAAGCAGCAAGACACCTTCTGTTAGGGACCCGAATGAGTGGGCCATGGCAAAA
AGTGGGTTTGCCTTTTCTTCTTCAGAACTACTGGACAATTCACCCAGTGAGATA
AACAATGAAGCAGCTCCAGAAATCTGGGGCAAGAAAAACAATGACTCCAGGGAT
CACATCTTTGCACCTGGAAATCCCAGTTCTGATCTGGATCACACATGGACTAAT
TCTAAGCCACCAAAAGAAGATCAGAATGGTTTAGTGGATCCTAAAACTAGGGGC
AAGGTATATGAAAAGGTAGACTCCTGGAACCTTTTTGAGGAGAATATGAAGAAA
GGAGGGTCAGATGTCCTAGTTCCTTGGGAAGATTCCTTCTTATCTTACAAATGT
TCTGATTACAGTGCATCCAACCTAGGAGAAGATTCGGTGCCTTCCCCCTTAGAT
ACCAATTATTCCACCTCAGACTCTTACACATCACCAACATTTGCTGGAGACGAA
AAGGAAACTGAACACAAGCCATTTGCTAAAGAGGAAGGTTTTGAGTCAAAAGAT
GGTAACTCCACGGCAGAGGAGACTGACATTCCTCCTCAGTCACTGCAACAGTCA
TCTCGAAATCGAATCAGTTCAGGTCCTGGGAACCTAGACATGTGGGCTTCACCT
CATACAGATAACAGTTCTGAAATAAATACCACTCACAACCTGGATGAAAATGAA
CTCAAGACAGAGCACACAGATGGTAAGAATATCTCCATGGAGGATGACGTCGGG
GAAAGCAGCCAGTCCAGTTACGACGACCCCAGCATGATGCAACTGTACAATGAA
ACAAACCGACAACTCACACTTTTGCACAGCAGCACCAACTCCCGGCAGACGGCC
CCTGACAGTCTCGACTTGTGGAACAGAGTGATTTTGGAGGATACTCAGTCCACT
GCAACGATCTCAGATATGGACAATGATTTGGACTGGGATGACTGCAGTGGGGGT
GCGGCAATCCCCAGTGATGGTCAAACAGAAGGATACATGGCTGAAGGTTCCGAG
CCGGAAACCCGATTTACAGTGAGACAGCTGGAACCCTGGGGCTTGGAGTATCAG
GAAGCAAATCAGGTAGATTGGGAGCTCCCTGCCTCTGATGAGCATACCAAGGAC
AGTGCTCCCAGTGAACATCACACATTGAATGAGAAAAGTGGGCAGCTAATTGCA
AACAGTATTTGGGATTCCGTCATGAGAGATAAGGACATGTCATCATTCATGTTA
CCAGGCTCCTCACATATCACAGATTCAGAGCAAAGGGAATTGCCTCCTGAAATC
CCCAGCCATTCAGCAAATGTTAAAGACACTCATTTCCCAGATGCGCCAGCAGCC
TCTGGAACCAGTGAATCAGAGGCACTTATATCTCATCTTGACAAGCAGGACACA
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GAGAGGGAAACCCTGCAAAGTGATGCAGCATCCTTGGCGACTAGGCTTGAGAAT
CCAGGGTATTTTCCACACCCAGATCCATGGAAAGGTCATGGCGATGGACAAAGT
GAAAGTGAGAAGGAAGCCCAGGGAGCCACTGACAGGGGGCACCTTGATGAAGAG
GAGGTGATCGCCTCTGGTGTGGAGAATGCCTCAGGGATTTCTGAAAAAGGGCAG
AGTGACCAGGAACTGTCTTCTCTGGTTGCATCTGAACATCAGGAAATCTGCATT
AAATCAGGCAAAATCAGCTCTCTTGCTGTCACTTTCAGTCCTCAAACCGAGGAA
CCAGAGGAAGTTTTAGAGTATGAGGAGGGGTCTTACAATCTAGACTCCCGTGAT
GTGCAAACAGGGATGTCCGCAGATAACCTGCAGCCAAAAGATACCCATGAAAAA
CACCTCATGAGTCAAAGAAATTCAGGTGAAACTACTGAGACTTCAGATGGGATG
AATTTCACAAAATATGTATCTGTACCTGAAAAGGATCTTGAGAAAACTGAAGAA
TGTAACTTTCTAGAGCCAGAGAACGTGGGTGGAGGGCCACCTCACAGAGTTCCC
CGAAGTCTTGACTTTGGGGACGTCCCTATAGACAGTGATGTGCATGTCAGCAGC
ACACGTTCTGAGATAACCAAAAATCTTGACGTTAAGGGGTCTGAAAATAGCCTT
CCAGGAGCCGGTTCGTCTGGAAATTTTGACAGAGATACTATTTCTAGTGAGTAT
ACTCATTCAAGTGCATCAAGTCCTGAGTTAAATGACTCTTCAGTTGCACTGTCC
TCCTGGGGCCAGCAACCCAGTTCTGGGTATCAAGAAGAAAACCAAGGCAACTGG
AGTGAACAGAATCACCAAGAATCTGAACTAATTACCACTGATGGCCAAGTAGAA
ATAGTTACCAAAGTGAAGGATTTAGAGAAAAACAGAATAAATGAGTTTGAAAAG
AGCTTTGATCGCAAAACTCCTACATTTTTAGAGATCTGGAATGACTCAGTTGAT
GGTGATTCCTTTTCCTCTTTATCCAGTCCTGAAACAGGCAAATATTCTGAACAT
TCAGGGACACATCAGGAAAGCAATCTAATTGCTAGCTACCAGGAGAAAAATGAA
CATGACATTTCTGCAACTGTGCAGCCAGAGGATGCCAGGGTCATTTCAACAAGC
TCAGGTTCTGATGATGACAGTGTCGGTGGTGAAGAGTCAATAGAGGAAGAGATC
CAGGTGGCCAACTGCCACGTTGCTGAGGATGAATCCAGAGCTTGGGATTCATTG
AATGAATCTAATAAGTTCTTGGTCACAGCTGATCCTAAGTCTGAAAATATTTAT
GACTACCTAGACAGCTCAGAGCCAGCAGAGAATGAGAATAAGTCAAACCCATTC
TGTGACAATCAACAAAGCAGCCCTGATCCCTGGACTTTCTCACCATTAACGGAG
ACTGAAATGCAGATTACAGCAGTGGAGAAGGAGAAGAGATCTTCTCCAGAAACA
GGGACAACAGGAGATGTTGCATGGCAAATATCTCCCAAAGCTTCGTTCCCAAAG
AACGAAGATAATTCTCAACTGGAAATGCTGGGCTTCTCAGCTGATAGCACTGAG
TGGTGGAAGGCCTCACCCCAGGAAGGGAGACTAATTGAAAGTCCATTTGAAAGG
GAGCTGTCTGACTCCAGTGGTGTGTTGGAGATAAATTCTTCAGTACACCAAAAT
GCCAGTCCCTGGGGAGTACCAGTTCAGGGTGATATTGAGCCCGTGGAAACACAC
TATACTAATCCTTTTAGTGACAACCATCAGTCACCCTTTCTGGAAGGTAATGGG
AAGAACTCCCATGAGCAACTCTGGAACATTCAACCAAGGCAGCCAGACCCAGAT
GCTGACAAGTTCAGCCAGCTTGTAAAATTAGACCAAATTAAAGAAAAGGACTCA
AGAGAGCAAACCTTTGTGTCTGCTGCTGGTGATGAGCTGACTCCTGAAACACCT
ACCCAAGAGCAGTGTCAGGACACCATGCTGCCAGTCTGTGATCATCCGGACGCA
GCCTTTACTCACGCAGAGGAAAATAGTTGTGTTACATCTAATGTTTCAACTAAT
GAAGGTCAAGAAACAAATCAGTGGGAACAAGAAAAATCATACCTAGGTGAGATG
ACAAATTCAAGCATTGCCACAGAAAATTTTCCTGCTGTCAGTTCTCCCACCCAA
CTGATAATGAAGCCAGGCTCTGAATGGGATGGCTCTACCCCAAGTGAGGACTCC
CGAGGTACCTTTGTGCCAGATATTTTACATGGCAACTTTCAAGAGGGTGGGCAG
CTGGCCTCTGCCGCGCCTGACTTGTGGATAGATGCTAAGAAGCCCTTCAGTTTG
AAAGCAGATGGTGAGAATCCTGATATCCTGACGCACTGCGAACATGACAGCAAT
TCTCAGGCTTCCGACAGCCCTGATATATGTCACGATTCTGAAGCAAAGGAAGAG
ACTGAGAAGCACCTCAGTGCTTGCATGGGACCTGAAGTGGAATCCAGTGAGCTT
TGTCTCACTGAGCCAGAGATAGATGAAGAACCCATTTATGAGCCTGGACGGGAG
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TTTGTCCCATCCAATGCAGAACTCGATTCTGAAAACGCAACTGTGCTGCCTCCA
ATTGGCTATCAAGCAGACATAAAGGGCTCCTCTCAGCCCACCTCTCATAAAGGT
TCACCTGAACCTTCTGAAATAAACGGTGACAACAGTACAGGTTTACAAGTATCA
GAAAAAGGAGCCAGCCCAGATATGGCACCAATTTTGGAACCAGTTGACAGAAGA
ATCCCAAGGATTGAAAATGTGGCAACTAGCATTTTTGTAACTCACCAAGAGCCA
ACTCCAGAAGGTGACGGTTCTTGGATATCAGACAGCTTTTCTCCTGAAAGTCAG
CCTGGTGCAAGAGCTTTGTTTGATGGTGATCCACATTTATCCACAGAGAATCCT
GCCTTGGTTCCTGATGCTTTGCTAGCCTCAGACACTTGTCTGGATATAAGCGAA
GCTGCCTTTGACCACAGTTTCAGCGATGCCTCAGGTCTCAACACATCCACGGGA
ACAATAGATGACATGAGTAAACTGACATTATCCGAAGGCCATCCGGAAACGCCA
GTTGATGGGGACCTAGGGAAGCAAGATATCTGCTCATCTGAAGCCTCGTGGGGT
GATTTTGAATATGATGTAATGGGCCAGAATATCGATGAAGATTTCCTGAGAGAG
CCTGAACACTTCCTGTATGGTGGTGACCCTCCTTTGGAGGAAGATTCTCTGAAG
CAGTCGCTGGCACCGTACACACCTCCCTTTGATTTGTCTTATCTCACAGAACCT
GCCCAGAGTGCTGAAACAATAGAGGAAGCTGGGTCTCCAGAGGATGAATCTCTG
GGATGCAGAGCAGCAGAGATAGTGCTTTCTGCACTTCCTGATCGAAGAAGTGAG
GGAAACCAGGCTGAGACCAAAAACAGACTGCCTGGATCCCAGCTGGCTGTGCTG
CATATTCGTGAAGACCCTGAGTCCGTTTATTTGCCGGTAGGAGCAGGCTCCAAC
ATTTTGTCTCCATCAAACGTTGACTGGGAAGTAGAAACAGATAATTCTGATTTA
CCAGCAGGTGGAGACATAGGACCACCAAATGGTGCCAGCAAGGAAATACCAGAA
TTGGAAGAAGAAAAAACAATTCCTACCAAAGAGCCTGAGCAGATAAAATCAGAA
TACAAGGAAGAAAGATGTACAGAGAAGAATGAAGATCGTCATGCACTACACATG
GATTACATACTTGTAAACCGTGAAGAAAATTCACACTCAAAGCCAGAGACCTGT
GAAGAAAGAGAAAGCATAGCTGAATTAGAATTGTATGTAGGTTCCAAAGAAACA
GGGATGCAGGGAACTCAGTTAGCAAGCTTCCCAGACACATGTCAGCCAGCCTCC
TTAAATGAAAGAAAAGGTCTCTCTGCAGAGAAAATGTCTTCTAAAGGCGATACG
AGATCATCTTTTGAAAGCCCTGCACAAGACCAGAGTTGGATGTTCTTGGGCCAT
AGCGAGGTTGGTGATCCATCACTGGATGCCAGGGACTCAGGGCCTGGGTGGTCT
GGCAAGACTGTGGAGCCGTTCTCTGAACTCGGCTTGGGTGAGGGTCCCCAGCTG
CAGATTCTGGAAGAAATGAAGCCTCTAGAATCTTTAGCACTAGAGGAAGCCTCT
GGTCCAGTCAGCCAATCACAGAAGAGTAAGAGCCGAGGCAGGGCTGGCCCGGAT
GCAGTTACCCATGACAATGAATGGGAAATGCTTTCACCACAGCCTGTTCAGAAA
AACATGATCCCTGACACGGAAATGGAGGAGGAGACAGAGTTCCTTGAGCTCGGA
ACCAGGATATCAAGACCAAATGGACTACTGTCAGAGGATGTAGGAATGGACATC
CCCTTTGAAGAGGGCGTGCTGAGTCCCAGTGCTGCAGACATGAGGCCTGAACCT
CCTAATTCTCTGGATCTTAATGACACTCATCCTCGGAGAATCAAGCTCACAGCC
CCAAATATCAATCTTTCTCTGGACCAAAGTGAAGGATCTATTCTCTCTGATGAT
AACTTGGACAGTCCAGATGAAATTGACATCAATGTGGATGAACTTGATACCCCC
GATGAAGCAGATTCTTTTGAGTACACTGGCCATGATCCCACAGCCAACAAAGAT
TCTGGCCAAGAGTCAGAGTCTATTCCAGAATATACGGCCGAAGAGGAACGGGAG
GACAACCGGCTTTGGAGGACAGTGGTCATTGGAGAACAAGAGCAGCGCATTGAC
ATGAAGGTCATCGAGCCCTACAGGAGAGTCATTTCTCACGGAGGAGATTCAGGA
TACTATGGGGACGGTCTAAATGCCATTATTGTGTTTGCCGCCTGTTTTCTGCCA
GACAGCAGTCGGGCGGATTACCACTATGTCATGGAAAATCTTTTCCTATATGTA
ATAAGTACTTTAGAGTTGATGGTAGCTGAAGACTATATGATTGTGTACTTGAAT
GGTGCAACCCCAAGAAGGAGGATGCCAGGGCTAGGCTGGATGAAGAAATGCTAC
CAGATGATTGACAGACGGTTGAGGAAGAATTTGAAATCATTCATCATTGTTCAT
CCATCTTGGTTCATCAGAACAATCCTTGCTGTGACACGACCTTTTATAAGTTCA
 113 
AAATTCAGCAGTAAAATTAAATATGTCAATAGCTTATCAGAACTCAGTGGGCTG
ATCCCAATGGATTGCATCCACATTCCAGAGAGCATCATCAATATTGACTTGAAG
CTGAAAGAAAAGCCTTAGTTGGCCATGCTGGAAGAAGAGGATGCTTTTCTGGTT
CATGGTTCTGTTGAAACATATCTACCTGAAAGAGACAGGGCTGATGTCACCTTT
TTCCACTTTGCACTACCTGGTGCCATTCTAAATTTCTAAGGGGAAAAATAGAAA
GTTTGTTTACTCTTAAGATATTTTATGAAATTGTGTGTACTTTCCTATTTTGCC
AATTATGTGCCTCAAAGATTTTAGTTGAGCCTTAGCAAGAAAGTAGGACCTTCC
ATTTCAATACTTCATTAACACGGTGTAGTGATACTTTGTCCCTTAGACTGGTGT
TTACCAGTAAGATACCTTTAATCCACTGTTAAGTATGAGTGGATTTGTTTCCAT
AGATTAGCTGGATTTCCTTTTGGTGATTGCATTAGGTTTAAAGTACACAGGTCT
CAACTCTCCCCAGGAAAGTTTCCCCTGTTTGACTCCACCTTTAAAATCCTAAGC
CTGACTAGGACAGCCACAAACCACACAAGGTGTAAAACCATCATCAGCTAAGTG
CCCGTTTTGTTCTTGTTTACCAGAATCTCCTTTAACTTCTCAAAGGGAAGCCGG
GCTTTCTAATCCACGTCAACTTTATTTTAGTTGTCAAATTGGGCATTATATTTT
ATGTAAATTGGTCTTTTAACATCATTTTCCTGATGAATGTTGGTGACCACCACA
TTGTGAAATTTAAGAATCCGTGTTGCATGTTTGGTAGCTCTCTGAGTTTCAGGC
CATAAACTCAGCTCCAGAGGTTACCTTTTAAGTGCCAAGAACTCAAGTGCAAGG
TGGCCTACTCAAAAATCATTTGGTAGCATTCAGTTATTCATGAATTCCTCTCTC
GCATGCATTATAAAAAGTGATCTGCTTTAAAACACCGTAATCTGATCATAGGCT
TAAAATTAAATATGAGTATTACTTTCATGTACAAAATATTTCCTTTATAGTCTT
CATATGCCCTTTAAAATGCCAACAAGATTTCAAGTCTGTAGGCCTCTAGTGAGG
TGGGGTGGCAAACCACAGCTAAGTCTCGCTCACCACTGCAAGCTAAGAATGGTT
TTTACATTTTGGGTTGGAAAAATTTTTTTTGAATATTTCATGACACATGAAAAT
TATTCAAATGTTAGTGCCGATAAATAAAGTGGTACTGAAACACAGCCACACAAA
CTTGTTTTTGTACTGTCTACAGCTACTTTCACACTACAGCCGCAGAGCTGAGCA
GTTCAGCAGACCGTATGTCCCACAATGCCTAAAACATTGACTATGTTTACAGAA
AAAGTTTGCTGACCCCTGCTCTAGCAAACGCATCCTTTCCTACTCCACCCCAAT
TTGTATTTAGATAGTTTCTCTAACAGAACGGACAAATGAGGCTGCAAACTAATT
TATTTTTGTCAAAAATCAATGTTTTGACATCCACAGACAGTGAAATAAAAGAAA
TGGCTTGCTGAAAAACATGAGGAGTCCTAGCCACAAAATCACTGCTTAGGTTGC
AATTGCCAAAATGAAGCCTTCTTAGAAGCACTTCTTTAGTATATACAGGTGTTG
GCTGAAGTCCGTGCCTCACTCTGGGAACCATTCTTAGTCTCCAGTGTCTCCTAT
TACAAAGAAGCTGGCAGAAATAAAAATGAAGGGGTGAGAGCGGTTCCACCCTAG
TCTCATGGTGGAAAATTCATTGGGGAGAGCTGTCCAGGATATTTGGAGTCCTGG
GTAGAAGGAGCTTGTAACTACTTTAAAGTCGACATCTTTGCACAGGTGATTGAG
TTTCTCTGACCTCATTGCTTCACCTCTGTCTCCTCCCGTCCTTCCGCACGTGCC
CACACACACGCAGTTCAGCCCTCTTTCCTCCATAAGCCTCCATCGTTTTCTCTT
TTCTCCTCTTGATCCTTTCAAGCGAGTATCTTGTTGAATTGTATGTTCTGTTGG
ATCTCCTCCTTCATAACATCTGGCTTGTTGGACAGAAAAACCCTACAGCCCACC
CCCTCCCACAGCCCACCTCCACTTTTGAAAGCCCAAATTACACCTCTCCCAGAA
CACAGTGTTGACGTAAATACAGTTACCCAATATTCCTGTTTGTTCACCTATTTG
CTACTTTCACTCAGTAGCATCCCATTTTGTAAAATGAATTCCATGGTCACCCTG
TCACAGGAAGTAATGAAAAATCCAGTGTTCAGTGTAGTGGTGCAAACCTGAGGG
CATAGAGCTGTTCATAGAGGGCTCTTGTTATAGCCAAACAGACACAGCAACAAT
CTCACCATTTATATATATATTTTTAACTTGTCCAGCTCATCTATGGAAAACTAC
TCAGGTGGTATGCTGTTTGAAGCCTCATCTTCCTACATGAAAATTATGGGCATT
TGTCCCAATGATTTTGTTTCAGCTGTTCTGTAGGCTGCATAACCACTCTGATAT
TTAGGTATCTGCTATTTTATTATCTTAAAAGACAAATTAATTTAATTGCATGTG
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CTAGGGAAAAGCTACCATGTACATTCACCCCAAGTAAATAGAATCCTAGATGAA
TCCTAGAAAAATAATCCCTAAGCAGATAGGTAGACAGAGGTAAACATTCACATG
ATTTAGCTCTCTAGCTCTTGCACTCTGAACATTCTTGCTTTGGTTCTGACTTCT
GGGAACTGCTTTGCATTTCTCCTATAGATCTGTAGTTAAGGGAACCAAGGGGTC
ATTGGGGCAAAAGCATTGTTTCTCAAAGCTCCTTGATTAAGAGAAAGAACAGAA
ATTTGCACAGAAGATAGTGTCAAGGAGTGAGAAAGTTTGTTTGAGGGCAGTAGC
TCAGTGTGGAAGAAAATCCTGAAGTTTCTGTTGAAGCCATACAATGTTCTATGG
GGTTACTCTCTAAGACATTCTCTGAGGTGTGTGAGGAAGTCACTACTCCTAGCC
TTTGTTAAGATGTAATTTTAAATATTCAGTTATGGTACTATGTTTGCAACTCTC
GTCTTATCACAATGCCTCAGTAGTTTGTTCCCTTAGAAACATTTAGATGTGCAC
AAATTAATCTTTTATATATCTAAAGGTTTTTCTATCATGCATTGGATTGCTCAG
AATAAAGTGTCTGTTAGACTTCGTTTTGG 
 
 
Sequence Translation: 3,057 amino acids 
MEEFLQRAKSKLNRSKRLEKVHVVIGPKSCDLDSLISTFTYAYFLDKVSPPGVL
CLPVLNIPRTEFNYFTETRFILEELNISESFHIFRDGINLHQLNDEGKLSITLV
GSSVLASEDKTLESAVVKVINPVEQSDANVEFRESSSSLVLKEILQEAPELITE
QLAHRLRGSILFKWMTMESEKISEKQEEILSILEEKFPNLPPREDIINVLQETQ
FSAQGLSIEQTMLKDLKELSDGEIKVAISTVNMNLENCLFHSNITSDLKAFTDK
FGFDVLILFSSYLSEEQQPRRQIAVYSENMELCSQICCELEECQNPCLELEPFD
CGCDEILVYQQEDPSVTCDQVVLVVKEVINRRCPEMVSNSRTSSTEAVAGSAPL
SQGSSGIMELYGSDIEPQPSSVNFIENPPDLNDSNQAQVDANVDLVSPDSGLAT
IRSSRSSKESSVFLSDDSPVGEGAGPHHTLLPGLDSYSPIPEGAVAEEHAWSGE
HGEHFDLFNFDPAPMASGQSQQSSHSADYSPADDFFPNSDLSEGQLPAGPEGLD
GMGTNMSNYSSSSLLSGAGKDSLVEHDEEFVQRQDSPRDNSERNLSLTDFVGDE
SPSPERLKNTGKRIPPTPMNSLVESSPSTEEPASLYTEDMTQKATDTGHMGPPQ
THARCSSWWGGLEIDSKNIADAWSSSEQESVFQSPESWKEHKPSSIDRRASDSV
FQPKSLEFTKSGPWESEFGQPELGSNDIQDKNEESLPFQNLPIEKSPLPNTSPQ
GTNHLIEDFASLWHSGRSPTAMPEPWGNPTDDGEPAAVAPFPAWSAFGKEDHDE
ALKNTWNLHPTSSKTPSVRDPNEWAMAKSGFAFSSSELLDNSPSEINNEAAPEI
WGKKNNDSRDHIFAPGNPSSDLDHTWTNSKPPKEDQNGLVDPKTRGKVYEKVDS
WNLFEENMKKGGSDVLVPWEDSFLSYKCSDYSASNLGEDSVPSPLDTNYSTSDS
YTSPTFAGDEKETEHKPFAKEEGFESKDGNSTAEETDIPPQSLQQSSRNRISSG
PGNLDMWASPHTDNSSEINTTHNLDENELKTEHTDGKNISMEDDVGESSQSSYD
DPSMMQLYNETNRQLTLLHSSTNSRQTAPDSLDLWNRVILEDTQSTATISDMDN
DLDWDDCSGGAAIPSDGQTEGYMAEGSEPETRFTVRQLEPWGLEYQEANQVDWE
LPASDEHTKDSAPSEHHTLNEKSGQLIANSIWDSVMRDKDMSSFMLPGSSHITD
SEQRELPPEIPSHSANVKDTHFPDAPAASGTSESEALISHLDKQDTERETLQSD
AASLATRLENPGYFPHPDPWKGHGDGQSESEKEAQGATDRGHLDEEEVIASGVE
NASGISEKGQSDQELSSLVASEHQEICIKSGKISSLAVTFSPQTEEPEEVLEYE
EGSYNLDSRDVQTGMSADNLQPKDTHEKHLMSQRNSGETTETSDGMNFTKYVSV
PEKDLEKTEECNFLEPENVGGGPPHRVPRSLDFGDVPIDSDVHVSSTRSEITKN
LDVKGSENSLPGAGSSGNFDRDTISSEYTHSSASSPELNDSSVALSSWGQQPSS
GYQEENQGNWSEQNHQESELITTDGQVIVTKVKDLEKNRINEFEKSFDRKTPTF
LEIWNDSVDGDSFSSLSSPETGKYSEHSGTHQESNLIASYQEKNEHDISATVQP
EDARVISTSSGSDDDSVGGEESIEEEIQVANCHVAEDESRAWDSLNESNKFLVT
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ADPKSENIYDYLDSSEPAENENKSNPFCDNQQSSPDPWTFSPLTETEMQITAVE
KEKRSSPETGTTGDVAWQISPKASFPKNEDNSQLEMLGFSADSTEWWKASPQEG
RLIESPFERELSDSSGVLEINSSVHQNASPWGVPVQGDIEPVETHYTNPFSDNH
QSPFLEGNGKNSHEQLWNIQPRQPDPDADKFSQLVKLDQIKEKDSREQTFVSAA
GDELTPETPTQEQCQDTMLPVCDHPDAAFTHAEENSCVTSNVSTNEGQETNQWE
QEKSYLGEMTNSSIATENFPAVSSPTQLIMKPGSEWDGSTPSEDSRGTFVPDIL
HGNFQEGGQLASAAPDLWIDAKKPFSLKADGENPDILTHCEHDSNSQASDSPDI
CHDSEAKEETEKHLSACMGPEVESSELCLTEPEIDEEPIYEPGREFVPSNAELD
SENATVLPPIGYQADIKGSSQPTSHKGSPEPSEINGDNSTGLQVSEKGASPDMA
PILEPVDRRIPRIENVATSIFVTHQEPTPEGDGSWISDSFSPESQPGARALFDG
DPHLSTENPALVPDALLASDTCLDISEAAFDHSFSDASGLNTSTGTIDDMSKLT
LSEGHPETPVDGDLGKQDICSSEASWGDFEYDVMGQNIDEDFLREPEHFLYGGD
PPLEEDSLKQSLAPYTPPFDLSYLTEPAQSAETIEEAGSPEDESLGCRAAEIVL
SALPDRRSEGNQAETKNRLPGSQLAVLHIREDPESVYLPVGAGSNILSPSNVDW
EVETDNSDLPAGGDIGPPNGASKEIPELEEEKTIPTKEPEQIKSEYKEERCTEK
NEDRHALHMDYILVNREENSHSKPETCEERESIAELELYVGSKETGMQGTQLAS
FPDTCQPASLNERKGLSAEKMSSKGDTRSSFESPAQDQSWMFLGHSEVGDPSLD
ARDSGPGWSGKTVEPFSELGLGEGPQLQILEEMKPLESLALEEASGPVSQSQKS
KSRGRAGPDAVTHDNEWEMLSPQPVQKNMIPDTEMEEETEFLELGTRISRPNGL
LSEDVGMDIPFEEGVLSPSAADMRPEPPNSLDLNDTHPRRIKLTAPNINLSLDQ
SEGSILSDDNLDSPDEIDINVDELDTPDEADSFEYTGHDPTANKDSGQESESIP
EYTAEEEREDNRLWRTVVIGEQEQRIDMKVIEPYRRVISHGGDSGYYGDGLNAI
IVFAACFLPDSSRADYHYVMENLFLYVISTLELMVAEDYMIVYLNGATPRRRMP
GLGWMKKCYQMIDRRLRKNLKSFIIVHPSWFIRTILAVTRPFISSKFSSKIKYV
NSLSELSGLIPMDCIHIPESIINIDLKLKEKP 
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B.2 PC-TSGC2 (GenBank accession number: FJ808773) 
 
 
Total bp: 12,217 
5’ UTR: 409 bp (1 – 409) 
Kozak sequence: 407 – 413 
ATG: 410 – 412 
Coding sequence (in blue): 8202 bp (410- 8611) 
Stop codon: 8609-8611 
3’ UTR:  3606 bp (8612 – 12217) 
 
Full-length cDNA sequence: 
 
ACCCCGCTCGTCTTCCTTGGGCCGAGATTTTCCACTGCGCCCCTCCGAGTACCC
GGGTTCCAAACCCCTAGCCACGACATGGAAGAATTTTTGCAACGCGCCAAATCT
AAACTGAATCGAAGCAAACGCTTGGAGAAGGTCCATGTGGTTATTGGGCCTAAA
TCGTGTGACTTGGATTCTCTCATTTCTACCTTCACATATGCTTACTTTCTAGAC
AAGTGAAGACAAAACTTTAGAATCAGCAGTTGTCAAAGTCATTAATCCGGTTGA
GCAGAGCGATGCCAACGTTGAGTTCCGAGAGTCTTCCTCTTCTCTCGTGCTAAA
GGAGATTCTCCAGGAGGCTCCTGAGCTCATCACCGAGCAACTGGCTCATCGCCT
CAGAGGTAGCATTCTTTTCAAGTGGATGACCATGGAATCAGAGAAGATCTCAGA
GAAGCAGGAGGAAATTCTTTCTATCCTGGAAGAAAAATTTCCTAACTTGCCTCC
AAGAGAGGACATCATCAACGTCCTACAGGAGACCCAGTTCAGTGCTCAGGGTTT
AAGTATTGAACAGACAATGTTGAAAGATCTAAAGGAGCTGTCAGATGGAGAAAT
AAAAGTGGCCATTAGTACTGTGAGCATGAACCTTGAGAATTGTCTATTTCACAG
CAATATTACCAGTGACTTGAAAGCATTTACAGACAAGTTTGGTTTTGATGTCCT
CATCCTGTTCTCCAGCTATCTGTCAGAGGAGCAGCAGCCGAGACGACAGATTGC
TGTGTACTCAGAAAACATGGAGCTGTGCAGTCAGATTTGCTGTGAGCTGGAAGA
GTGTCAGAACCCTTGCCTAGAACTGGAGCCCTTTGACTGTGGCTGTGATGAGAT
CCTGGTGTACCAACAAGAGGACCCTTCAGTGACTTGTGATCAGGTGGTTCTCGT
TGTCAAGGAAGTCATCAACAGGAGGTGTCCAGAGATGGTCTCCAATAGCCGGAC
ATCCTCAACAGAAGCCGTGGCAGGCAGTGCCCCCCTCTCCCAGGGGTCTTCTGG
GATTATGGAATTGTATGGTTCTGACATAGAGCCACAACCCAGCTCTGTGAATTT
CATAGAGAACCCTCCAGATCTCAATGATTCTAACCAGGCTCAGGTGGATGCCAA
TGTAGACCTTGTTAGCCCAGACAGCGGACTGGCTACCATTAGGAGCAGCCGCTC
ATCCAAGGAGAGCTCTGTTTTCCTCAGTGACGACAGCCCCGTGAGAGAAGGTGC
 117 
TGGGCCTCACCACACCCTTCTCCCAGGGCTTGACTCCTACAGCCCCATCCCTGA
AGGGGCGGTAGCGGAGGAACATGCATGGTCTGGAGAACACGGTGAGCACTTCGA
CCTCTTCAATTTTGACCCAGCACCCATGGCTTCTGGGCAGTCCCAGCAATCTTC
TCATTCTGCAGACTACTCCCCAGCAGATGACTTCTTCCCCAACAGCGACCTGTC
AGAAGGACAGCTCCCCGCTGGGCCTGAAGGACTTGATGGCATGGGAACCAACAT
GTCTAATTATTCATCCAGTTCACTTTTGTCAGGGGCTGGCAAAGATAGCCTTGT
GGAACATGATGAGGAGTTTGTCCAGAGACAAGACAGTCCCAGAGATAACTCTGA
AAGAAATTTGAGCCTGACAGATTTTGTGGGAGATGAATCCCCTTCCCCAGAAAG
GCTAAAAAATACTGGAAAGAGGATCCCACCAACACCCATGAATAGTTTAGTAGA
AAGCTCGCCATCCACTGAAGAACCAGCCTCACTCTATACCGAAGATATGACCCA
AAAAGCAACTGACACAGGTCACATGGGGCCACCTCAGACCCATGCACGGTGCAG
CAGCTGGTGGGGTGGTTTGGAAATTGACTCCAAAAATATTGCAGATGCGTGGAG
TTCCAGTGAACAGGAATCTGTTTTCCAGAGCCCTGAATCATGGAAAGAGCATAA
GCCAAGCTCCATTGATAGGAGAGCCTCAGATTCTGTATTTCAACCAAAGAGCCT
CGAATTTACAAAGTCAGGTCCCTGGGAGTCTGAATTTGGTCAGCCTGAACTGGG
TAGCAATGATATTCAAGACAAAAATGAGGAAAGCTTGCCGTTCCAGAACCTGCC
CATAGAGAAGTCACCTTTGCCAAATACATCTCCCCAAGGAACAAACCACCTGAT
AGAAGACTTTGCTTCTTTGTGGCATTCTGGTCGCTCTCCCACAGCCATGCCCGA
GCCCTGGGGAAATCCTACAGATGATGGTGAACCAGCAGCTGTGGCGCCATTCCC
AGCCTGGAGTGCATTTGGTAAAGAAGATCATGATGAAGCTTTAAAAAATACCTG
GAATTTGCACCCAACAAGCAGCAAGACACCTTCTGTTAGGGACCCGAATGAGTG
GGCCATGGCAAAAAGTGGGTTTGCCTTTTCTTCTTCAGAACTACTGGACAATTC
ACCCAGTGAGATAAACAATGAAGCAGCTCCAGAAATCTGGGGCAAGAAAAACAA
TGACTCCAGGGATCACATCTTTGCACCTGGAAATCCCAGTTCTGATCTGGATCA
CACATGGACTAATTCTAAGCCACCAAAAGAAGATCAGAATGGTTTAGTGGATCC
TAAAACTAGGGGCAAGGTATATGAAAAGGTAGACTCCTGGAACCTTTTTGAGGA
GAATATGAAGAAAGGAGGGTCAGATGTCCTAGTTCCTTGGGAAGATTCCTTCTT
ATCTTACAAATGTTCTGATTACAGTGCATCCAACCTAGGAGAAGATTCGGTGCC
TTCCCCCTTAGATACCAATTATTCCACCTCAGACTCTTACACATCACCAACATT
TGCTGGAGACGAAAAGGAAACTGAACACAAGCCATTTGCTAAAGAGGAAGGTTT
TGGGTCAAAAGATGGTAACTCCACGGCAGAGGAGACTGACATTCCTCCTCAGTC
ACTGCAACAGTCATCTCGAAATCGAATCAGTTCAGGTCCTGGGAACCTAGACAT
GTGGGCTTCACCTCATACAGATAACAGTTCTGAAATAAATACCACTCACAACCT
GGATGAAAATGAACTCAAGACAGAGCACACAGATGGTAAGAATATCTCCATGGA
GGATGACGTCGGGGAAAGCAGCCAGTCCAGTTACGACGACCCCAGCATGATGCA
ACTGTACAATGAAACAAACCGACAACTCACACTTTTGCACAGCAGCACCAACTC
CCGGCAGACGGCCCCTGACAGTCTCGACTTGTGGAACAGAGTGATTTTGGAGGA
TACTCAGTCCACTGCAACGATCTCAGATATGGACAATGATTTGGACTGGGATGA
CTGCAGTGGGGGTGCGGCAATCCCCAGTGATGGTCAAACAGAAGGATACATGGC
TGAAGGTTCCGAGCCGGAAACCCGATTTACAGTGAGACAGCTGGAACCCTGGGG
CTTGGAGTATCAGGAAGCAAATCAGGTAGATTGGGAGCTCCCTGCCTCTGATGA
GCATACCAAGGACAGTGCTCCCAGTGAACATCACACATTGAATGAGAAAAGTGG
GCAGCTAATTGCAAACAGTATTTGGGATTCTGTCATGAGAGATAAAGACATGTC
ATCATTCATGTTACCAGGCTCCTCACATATCACAGATTCAGAGCAAAGGGAATT
GCCTCCTGAAATCCCCAGCCATTCAGCAAATGTTAAAGACACTCATTCCCCAGA
TGCGCCAGCAGCCTCTGGAACCAGTGAATCAGAGGCACTTATATCTCATCTTGA
CAAGCAGGACACAGAGAGGGAAACCCTGCAAAGTGATGCAGCATCCTTGGCGAC
TAGGCTTGAGAATCCAGGGTATTTTCCACACCCAGATCCATGGAAAGGTCATGG
 118 
CGATGGACAAAGTGAAAGTGAGAAGGAAGCCCAGGGAGCCACTGACAGGGGGCA
CCTTGATGAAGAGGAGGTGATCGCCTCTGGTGTGGAGAATGCCTCAGGGATTTC
TGAAAAAGGGCAGAGTGACCAGGAACTGTCTTCTCTGGTTGCATCTGAACATCA
GGAAATCTGCATTAAATCAGGCAAAATCAGCTCTCTTGCTGTCACTTTCAGTCC
TCAAACCGAGGAACCAGAGGAAGTTTTAGAGTATGAGGAGGGGTCTTACAATCT
AGACTCCCGTGATGTGCAAACAGGGATGTCCGCAGATAACCTGCAGCCAAAAGA
TACCCATGAAAAACACCTCATGAGTCAAAGAAATTCAGGTGAAACTACTGAGAC
TTCAGATGGGATGAATTTCACAAAATATGTATCTGTACCTGAAAAGGATCTTGA
GAAAACTGAAGAATGTAACTTTCTAGAGCCAGAGAACGTGGGTGGAGGGCCACC
TCACAGAGTTCCCCGAAGTCTTGACTTTGGGGACGTCCCTATAGACAGTGATGT
GCATGTCAGCAGCACACGTTCTGAGATAACCAAAAATCTTGACGTTAAGGGGTC
TGAAAATAGCCTTCCAGGAGCCGGTTCGTCTGGAAATTTTGACAGAGATACTAT
TTCTAGTGAGTATACTCATTCAAGTGCATCAAGTCCTGAGTTAAATGACTCTTC
AGTTGCACTGTCCTCCTGGGGCCAGCAACCCAGTTCTGGGTATCAAGAAGAAAA
CCAAGGCAACTGGAGTGAACAGAATCACCAAGAATCTGAACTAATTACCACTGA
TGGCCAAGTAGAAATAGTTACCAAAGTGAAGGATTTAGAGAAAAACAGAATAAA
TGAGTTTGAAAAGAGCTTTGATCGCAAAACTCCTACATTTTTAGAGATCTGGAA
TGACTCAGTTGATGGTGATTCCTTTTCCTCTTTATCCAGTCCTGAAACAGGCAA
ATATTCTGAACATTCAGGGACACATCAGGAAAGCAATCTAATTGCTAGCTACCA
GGAGAAAAATGAACATGACATTTCTGCAACTGTGCAGCCAGAGGATGCCAGGGT
CATTTCAACAAGCTCAGGTTCTGATGATGACAGTGTCGGTGGTGAAGAGTCAAT
AGAGGAAGAGATCCAGGTGGCCAACTGCCACGTTGCTGAGGATGAATCCAGAGC
TTGGGATTCATTGAATGAATCTAATAAGTTCTTGGTCACAGCTGATCCTAAGTC
TGAAAATATTTATGACTACCTAGACAGCTCAGAGCCAGCAGAGAATGAGAATAA
GTCAAACCCATTCTGTGACAATCAACAAAGCAGCCCTGATCCCTGGACTTTCTC
ACCATTAACGGAGACTGAAATGCAGATTACAGCAGTGGAGAAGGAGAAGAGATC
TTCTCCAGAAACAGGGACAACAGGAGATGTTGCATGGCAAATATCTCCCAAAGC
TTCGTTCCCAAAGAACGAAGATAATTCTCAACTGGAAATGCTGGGCTTCTCAGC
TGATAGCACTGAGTGGTGGAAGGCCTCACCCCAGGAAGGGAGACTAATTGAAAG
TCCATTTGAAAGGGAGCTGTCTGACTCCAGTGGTGTGTTGGAGATAAATTCTTC
AGTACACCAAAATGCCAGTCCCTGGGGAGTACCAGTTCAGGGTGATATTGAGCC
CGTGGAAACACACTATACTAATCCTTTTAGTGACAACCATCAGTCACCCTTTCT
GGAAGGTAATGGGAAGAACTCCCATGAGCAACTCTGGAACATTCAACCAAGGCA
GCCAGACCCAGATGCTGACAAGTTCAGCCAGCTTGTAAAATTAGACCAAATTAA
AGAAAAGGACTCAAGAGAGCAAACCTTTGTGTCTGCTGCTGGTGATGAGCTGAC
TCCTGAAACACCTACCCAAGAGCAGTGTCAGGACACCATGCTGCCAGTCTGTGA
TCATCCGGACGCAGCCTTTACTCACGCAGAGGAAAATAGTTGTGTTACATCTAA
TGTTTCAACTAATGAAGGTCAAGAAACAAATCAGTGGGAACAAGAAAAATCATA
CCTAGGTGAGATGACAAATTCAAGCATTGCCACAGAAAATTTTCCTGCTGTCAG
TTCTCCCACCCAACTGATAATGAAGCCAGGCTCTGAATGGGATGGCTCTACCCC
AAGTGAGGACTCCCGAGGTACCTTTGTGCCAGATATTTTACATGGCAACTTTCA
AGAGGGTGGGCAGCTGGCCTCTGCCGCGCCTGACTTGTGGATAGATGCTAAGAA
GCCCTTCAGTTTGAAAGCAGATGGTGAGAATCCTGATATCCTGACGCACTGCGA
ACATGACAGCAATTCTCAGGCTTCCGACAGCCCTGATATATGTCACGATTCTGA
AGCAAAGGAAGAGACTGAGAAGCACCTCAGTGCTTGCATGGGACCTGAAGTGGA
ATCCAGTGAGCTTTGTCTCACTGAGCCAGAGATAGATGAAGAACCCATTTATGA
GCCTGGACGGGAGTTTGTCCCATCCAATGCAGAACTCGATTCTGAAAACGCAAC
TGTGCTGCCTCCAATTGGCTATCAAGCAGACATAAAGGGCTCCTCTCAGCCCAC
 119 
CTCTCATAAAGGTTCACCTGAACCTTCTGAAATAAACGGTGACAACAGTACAGG
TTTACAAGTATCAGAAAAAGGAGCCAGCCCAGATATGGCACCAATTTTGGAACC
AGTTGACAGAAGAATCCCAAGGATTGAAAATGTGGCAACTAGCATTTTTGTAAC
TCACCAAGAGCCAACTCCAGAAGGTGACGGTTCTTGGATATCAGACAGCTTTTC
TCCTGAAAGTCAGCCTGGTGCAAGAGCTTTGTTTGATGGTGATCCACATTTATC
CACAGAGAATCCTGCCTTGGTTCCTGATGCTTTGCTAGCCTCAGACACTTGTCT
GGATATAAGCGAAGCTGCCTTTGACCACAGTTTCAGCGATGCCTCAGGTCTCAA
CACATCCACGGGAACAATAGATGACATGAGTAAACTGACATTATCCGAAGGCCA
TCCGGAAACGCCAGTTGATGGGGACCTAGGGAAGCAAGATATCTGCTCATCTGA
AGCCTCGTGGGGTGATTTTGAATATGATGTAATGGGCCAGAATATCGATGAAGA
TTTCCTGAGAGAGCCTGAACACTTCCTGTATGGTGGTGACCCTCCTTTGGAGGA
AGATTCTCTGAAGCAGTCGCTGGCACCGTACACACCTCCCTTTGATTTGTCTTA
TCTCACAGAACCTGCCCAGAGTGCTGAAACAATAGAGGAAGCTGGGTCTCCAGA
GGATGAATCTCTGGGATGCAGAGCAGCAGAGATAGTGCTTTCTGCACTTCCTGA
TCGAAGAAGTGAGGGAAACCAGGCTGAGACCAAAAACAGACTGCCTGGATCCCA
GCTGGCTGTGCTGCATATTCGTGAAGACCCTGAGTCCGTTTATTTGCCGGTAGG
AGCAGGCTCCAACATTTTGTCTCCATCAAACGTTGACTGGGAAGTAGAAACAGA
TAATTCTGATTTACCAGCAGGTGGAGACATAGGACCACCAAATGGTGCCAGCAA
GGAAATACCAGAATTGGAAGAAGAAAAAACAATTCCTACCAAAGAGCCTGAGCA
GATAAAATCAGAATACAAGGAAGAAAGATGTACAGAGAAGAATGAAGATCGTCA
TGCACTACACATGGATTACATACTTGTAAACCGTGAAGAAAATTCACACTCAAA
GCCAGAGACCTGTGAAGAAAGAGAAAGCATAGCTGAATTAGAATTGTATGTAGG
CTCCAAAGAAACAGGGCTGCAGGGAACTCAGTTAGCAAGCTTCCCAGACACATG
TCAGCCAGCCTCCTTAAATGAAAGAAAAGGTCTCTCTGCAGAGAAAATGTCTTC
TAAAGGCGATACGAGATCATCTTTTGAAAGCCCTGCACAAGACCAGAGTTGGAT
GTTCTTGGGCCATAGTGAGGTTGGTGATCCATCACTGGATGCCAGGGACTCAGG
GCCTGGGTGGTCTGGCAAGACTGTGGAGCCGTTCTCTGAACTCGGCTTGGGTGA
GGGTCCCCAGCTGCAGATTCTGGAAGAAATGAAGCCTCTAGAATCTTTAGCACT
AGAGGAAGCCTCTGGTCCAGTCAGCCAATCACAGAAGAGTAAGAGCCGAGGCAG
GGCTGGCCCGGGTGCAGTTACCCATGACAATGAATGGGAAATGCTTTCACCACA
GCCTGTTCAGAAAAACATGATCCCTGACACGGAAATGGAGGAGGAGACAGAGTT
CCTTGAGCTCGGAACCAGGATATCAAGACCAAATGGACTACTGTCAGAGGATGT
AGGAATGGACATCCCCTTTGAAGAGGGCGTGCTGAGTCCCAGTGCTGCAGACAT
GAGGCCTGAACCTCCTAATTCTCTGGATCTTAATGACACTCATCCTCGGAGAAT
CAAGCTCACAGCCCCAAATATCAATCTTTCTCTGGACCAAAGTGAAGGATCTAT
TCTCTCTGATGATAACTTGGACAGTCCAGATGAAATTGACATCAATGTGGATGA
ACTTGATACCCCCGATGAAGCAGATTCTTTTGAGTACACTGGCCATGATCCCAC
AGCCAACAAAGATTCTGGCCAAGAGTCAGAGTCTATTCCAGAATATACGGCCGA
AGAGGAACGGGAGGACAACCGGCTTCGGAGGACAGTGGTCATTGGAGAACAAGA
GCAGCGCATTGACATGAAGGTCATCGAGCCCTACAGGAGAGTCATTTCTCACGG
AGGAGATTCAGGTAACCTTCTCTGAAGTCTTGCTGGACAAATGACCCTGGAAAG
AATGAGGAGAAGAGTTGCTGGCTGGTGTGTGTGTGTGTATGTTTTGGTTGCGAC
TGTGACATCTTTCCTTCTGTCTCCATTCCATTGCTGGCCAGCAAACTTGTGTTA
CATCCCTTTCATGCCTGTCTGTGTCACTCAGATATGTAATAAGTACTTTAGAGT
TGATGGTAGCTGAAGACTATATGATTGTGTACTTGAATGGTGCAACCCCAAGAA
GGAGGATGCCAGGGCTAGGCTGGATGAAGAAATGCTACCAGATGATTGACAGAC
GGTTGAGGAAGAATTTGAAATCATTCATCATTGTTCATCCATCTTGGTTCATCA
GAACAATCCTTGCTGTGACACGACCTTTTATAAGTTCAAAATTCAGCAGTAAAA
 120 
TTAAATATGTCAATAGCTTATCAGAACTCAGTGGGCTGATCCCAATGGATTGCA
TCCACATTCCAGAGAGCATCATCAATATTGACTTGAAGCTGAAAGAAAAGCCTT
AGTTGGCCATGCTGGAAGAAGAGGATGCTTTTCTGGTTCATGGTTCTGTTGAAA
CATATCTACCTGAAAGAGACAGGGCTGATGTTACCTTTTTCCACTTTGCACTAC
CTGGTGCCATTCTAAATTTCTAAGGGGAAAAATAGAAAGTTTGTTTACTCTTAA
GATATTTTATGAAATTGTGTGTACTTTCCTATTTTGCCAATTATGTGCCTCAAA
GATTTTAGTTGAGCCTTAGCAAGAAAGTAGGACCTTCCATTTCAATACTTCATT
AACACGGTGTAGTGATACTTTGTCCCTTAGACTGGTGTTTACCAGTAAGATACC
TTTAATCCACTGTTAAGTATGAGTGGATTTGTTTCCATAGATTAGCTGGATTTC
CTTTTGGTGATTGCATTAGGTTTAAAGTACACAGGTCTCAACTCTCCCCAGGAA
AGTTTCCCCTGTTTGACTCCACCTTTAAAATCCTAAGCCTGACTAGGACAGCCA
CAAACCACACAAGGTGTAAAACCATCATCAGCTAAGTGCCCGTTTTGTTCTTGT
TTACCAGAATCTCCTTTAACTTCTCAAAGGGAAGCCGGGCTTTCTAATCCACGT
CAACTTTATTTTAGTTGTCAAATTGGGCATTATATTTTATGTAAATTGGTCTTT
TAACATCATTTTCCTGATGAATGTTGGTGACCACCACATTGTGAAATTTAAGAA
TCCGTGTTGCATGTTTGGTAGCTCTCTGAGTTTCAGGCCATAAACTCAGCTCCA
GAGGTTACCTTTTAAGTGCCAAGAACTCAAGTGCAAGGTGGCCTACTCAAAAAT
CATTTGGTAGCATTCAGTTATTCATGAATTCCTCTCTCGCATGCATTATAAAAA
GTGATCTGCTTTAAAACACCGTAATCTGATCATAGGCTTAAAATTAAATATGAG
TATTACTTTCATGTACAAAATATTTCCTTTATAGTCTTCATATGCCCTTTAAAA
TGCCAACAAGATTTCAAGTCTGTAGGCCTCTAGTGAGGTGGGGTGGCAAACCAC
AGCTAAGTCTCGCTCACCACTGCAAGCTAAGAATGGTTTTTACATTTTGGGTTG
GAAAAATTTTTTTTGAATATTTCATGACACATGAAAATTATTCAAATGTTAGTG
CCGATAAATAAAGTGGTACTGAAACACAGCCACACAAACTTGTTTTTGTACTGT
CTACAGCTACTTTCACACTACAGCCGCAGAGCTGAGCAGTTCAGCAGACCGTAT
GTCCCACAATGCCTAAAACATTGACTATGTTTACAGAAAAAGTTTGCTGACCCC
TGCTCTAGCAAACGCATCCTTTCCTACTCCACCCCAATTTGTATTTAGATAGTT
TCTCTAACAGAACGGACAAATGAGGCTGCAAACTAATTTATTTTTGTCAAAAAT
CAATGTTTTGACATCCACAGACAGTGAAATAAAAGAAATGGCTTGCTGAAAAAC
ATGAGGAGTCCTAGCCACAAAATCACTGCTTAGGTTGCAATTGCCAAAATGAAG
CCTTCTTAGAAGCACTTCTTTAGTATATACAGGTGTTGGCTGAAGTCCGTGCCT
CACTCTGGGAACCATTCTTAGTCTCCAGTGTCTCCTATTACAAAGAAGCTGGCA
GAAATAAAAATGAAGGGGTGAGAGCGGTTCCACCCTAGTCTCATGGTGGAAAAT
TCATTGGGGAGAGCTGTCCAGGATATTTGGAGTCCTGGGTAGAAGGAGCTTGTA
ACTACTTTAAAGTCGACATCTTTGCACAGGTGATTGAGTTTCTCTGACCTCATT
GCTTCACCTCTGTCTCCTCCCGTCCTTCCGCACGTGCCCACACACACGCAGTTC
AGCCCTCTTTCCTCCATAAGCCTCCATCGTTTTCTCTTTTCTCTTCTTGATCCT
TTCAAGCGAGTATCTTGTTGAATTGTATGTTCTGTTGGATCTCCTCCTTCATAA
CATCTGGCTTGTTGGACAGAAAAACCCTACAGCCCACCCCCTCCCACAGCCCAC
CTCCACTTTTGAAAGCCCAAATTACACCTCTCCCAGAACACAGTGTTGACGTAA
ATACAGTTACCCAATATTCCTGTTTGTTCACCTATTTGCTACTTTCACTCAGTA
GCATCCCATTTTGTAAAATGAATTCCATGGTCACCCTGTCACAGGAAGTAATGA
AAAATCCAGTGTTCAGTGTAGTGGTGCAAACCTGAGGGCATAGAGCTGTTCATA
GAGGGCTCTTGTTATAGCCAAACAGACACAGCAACAATCTCACCATTTATATAT
ATATTTTTAACTTGTCCAGCTCATCTATGGAAAACTACTCAGGTGGTATGCTGT
TTGAAGCCTCATCTTCCTACATGAAAATTATGGGCATTTGTCCCAATGATTTTG
TTTCAGCTGTTCTGTAGGCTGCATAACCACTCTGATATTTAGGTATCTGCTATT
TTATTATCTTAAAAGACAAATTAATTTAATTGCATGTGCTAGGGAAAAGCTACC
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ATGTACATTCACCCCAAGTAAATAGAATCCTAGATGAATCCTAGAAAAATAATC
CCTAAGCAGATAGGTAGACAGAGGTAAACATTCACATGATTTAGCTCTCTAGCT
CTTGCACTCTGAACATTCTTGCTTTGGGTCTGACTTCTGGGAACTGCTTTGCAT
TTCTCCTATAGATCTGTAGTTAAGGGAACCAAGGGGTCATTGGGGCAAAAGCAT
TGTTTCTCAAAGCTCCTTGATTAAGAGAAAGAACAGAAATTTGCACAGAAGATA
GTGTCAAGGAGTGAGAAAGTTTGTTTGAGGGCAGTAGCTCAGTGTGGAAGAAAA
TCCTGAAGTTTCTGTTGAAGCCATACAATGTTCTATGGGGTTACTCTCTAAGAC
ATTCTCTGAGGTGTGTGAGGAAGTCACTACTCCTAGCCTTTGTTAAGATGTAAT
TTTAAATATTCAGTTATGGTACTATGTTTGCAACTCTCGTCTTATCACAATGCC
TCAGTAGTTTGTTCCCTTAGAAACATTTAGATGTGCACAAATTAATCTTTTATA
TATCTAAAGGTTTTTCTATCATGCATTGGATTGCTCAGAATAAAGTGTCTGTTA
GACTTCGTTTTGG 
 
 
Sequence translation: 2,733 amino acids 
MESEKISEKQEEILSILEEKFPNLPPREDIINVLQETQFSAQGLSIEQTMLKDL
KELSDGEIKVAISTVSMNLENCLFHSNITSDLKAFTDKFGFDVLILFSSYLSEE
QQPRRQIAVYSENMELCSQICCELEECQNPCLELEPFDCGCDEILVYQQEDPSV
TCDQVVLVVKEVINRRCPEMVSNSRTSSTEAVAGSAPLSQGSSGIMELYGSDIE
PQPSSVNFIENPPDLNDSNQAQVDANVDLVSPDSGLATIRSSRSSKESSVFLSD
DSPVREGAGPHHTLLPGLDSYSPIPEGAVAEEHAWSGEHGEHFDLFNFDPAPMA
SGQSQQSSHSADYSPADDFFPNSDLSEGQLPAGPEGLDGMGTNMSNYSSSSLLS
GAGKDSLVEHDEEFVQRQDSPRDNSERNLSLTDFVGDESPSPERLKNTGKRIPP
TPMNSLVESSPSTEEPASLYTEDMTQKATDTGHMGPPQTHARCSSWWGGLEIDS
KNIADAWSSSEQESVFQSPESWKEHKPSSIDRRASDSVFQPKSLEFTKSGPWES
EFGQPELGSNDIQDKNEESLPFQNLPIEKSPLPNTSPQGTNHLIEDFASLWHSG
RSPTAMPEPWGNPTDDGEPAAVAPFPAWSAFGKEDHDEALKNTWNLHPTSSKTP
SVRDPNEWAMAKSGFAFSSSELLDNSPSEINNEAAPEIWGKKNNDSRDHIFAPG
NPSSDLDHTWTNSKPPKEDQNGLVDPKTRGKVYEKVDSWNLFEENMKKGGSDVL
VPWEDSFLSYKCSDYSASNLGEDSVPSPLDTNYSTSDSYTSPTFAGDEKETEHK
PFAKEEGFGSKDGNSTAEETDIPPQSLQQSSRNRISSGPGNLDMWASPHTDNSS
EINTTHNLDENELKTEHTDGKNISMEDDVGESSQSSYDDPSMMQLYNETNRQLT
LLHSSTNSRQTAPDSLDLWNRVILEDTQSTATISDMDNDLDWDDCSGGAAIPSD
GQTEGYMAEGSEPETRFTVRQLEPWGLEYQEANQVDWELPASDEHTKDSAPSEH
HTLNEKSGQLIANSIWDSVMRDKDMSSFMLPGSSHITDSEQRELPPEIPSHSAN
VKDTHSPDAPAASGTSESEALISHLDKQDTERETLQSDAASLATRLENPGYFPH
PDPWKGHGDGQSESEKEAQGATDRGHLDEEEVIASGVENASGISEKGQSDQELS
SLVASEHQEICIKSGKISSLAVTFSPQTEEPEEVLEYEEGSYNLDSRDVQTGMS
ADNLQPKDTHEKHLMSQRNSGETTETSDGMNFTKYVSVPEKDLEKTEECNFLEP
ENVGGGPPHRVPRSLDFGDVPIDSDVHVSSTRSEITKNLDVKGSENSLPGAGSS
GNFDRDTISSEYTHSSASSPELNDSSVALSSWGQQPSSGYQEENQGNWSEQNHQ
ESELITTDGQVEIVTKVKDLEKNRINEFEKSFDRKTPTFLEIWNDSVDGDSFSS
LSSPETGKYSEHSGTHQESNLIASYQEKNEHDISATVQPEDARVISTSSGSDDD
SVGGEESIEEEIQVANCHVAEDESRAWDSLNESNKFLVTADPKSENIYDYLDSS
EPAENENKSNPFCDNQQSSPDPWTFSPLTETEMQITAVEKEKRSSPETGTTGDV
AWQISPKASFPKNEDNSQLEMLGFSADSTEWWKASPQEGRLIESPFERELSDSS
 122 
GVLEINSSVHQNASPWGVPVQGDIEPVETHYTNPFSDNHQSPFLEGNGKNSHEQ
LWNIQPRQPDPDADKFSQLVKLDQIKEKDSREQTFVSAAGDELTPETPTQEQCQ
DTMLPVCDHPDAAFTHAEENSCVTSNVSTNEGQETNQWEQEKSYLGEMTNSSIA
TENFPAVSSPTQLIMKPGSEWDGSTPSEDSRGTFVPDILHGNFQEGGQLASAAP
DLWIDAKKPFSLKADGENPDILTHCEHDSNSQASDSPDICHDSEAKEETEKHLS
ACMGPEVESSELCLTEPEIDEEPIYEPGREFVPSNAELDSENATVLPPIGYQAD
IKGSSQPTSHKGSPEPSEINGDNSTGLQVSEKGASPDMAPILEPVDRRIPRIEN
VATSIFVTHQEPTPEGDGSWISDSFSPESQPGARALFDGDPHLSTENPALVPDA
LLASDTCLDISEAAFDHSFSDASGLNTSTGTIDDMSKLTLSEGHPETPVDGDLG
KQDICSSEASWGDFEYDVMGQNIDEDFLREPEHFLYGGDPPLEEDSLKQSLAPY
TPPFDLSYLTEPAQSAETIEEAGSPEDESLGCRAAEIVLSALPDRRSEGNQAET
KNRLPGSQLAVLHIREDPESVYLPVGAGSNILSPSNVDWEVETDNSDLPAGGDI
GPPNGASKEIPELEEEKTIPTKEPEQIKSEYKEERCTEKNEDRHALHMDYILVN
REENSHSKPETCEERESIAELELYVGSKETGLQGTQLASFPDTCQPASLNERKG
LSAEKMSSKGDTRSSFESPAQDQSWMFLGHSEVGDPSLDARDSGPGWSGKTVEP
FSELGLGEGPQLQILEEMKPLESLALEEASGPVSQSQKSKSRGRAGPGAVTHDN
EWEMLSPQPVQKNMIPDTEMEEETEFLELGTRISRPNGLLSEDVGMDIPFEEGV
LSPSAADMRPEPPNSLDLNDTHPRRIKLTAPNINLSLDQSEGSILSDDNLDSPD
EIDINVDELDTPDEADSFEYTGHDPTANKDSGQESESIPEYTAEEEREDNRLRR
TVVIGEQEQRIDMKVIEPYRRVISHGGDSGNLL 
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